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ABSTRACT 
 
The EDEN project is an interdisciplinary effort conceived to address key issues that have 
hampered sound hazard and risk assessment for endocrine disrupting chemicals (EDCs) 
in the European Union. It has adopted an approach that fully integrates human, wildlife, 
exposures, mechanisms and low-dose/mixture evaluations. The project was structured 
into four interlocking themes focusing on EDC mixture exposures, mechanisms of action 
and novel endpoints, effects on male reproductive health and the evaluation of low-dose 
and mixture effects of EDCs. 
 
For the first time, the simultaneous occurrence of nearly 150 different EDCs in human 
and wildlife tissues was measured. These studies revealed that numerous EDCs occur 
together in humans, yet differences in the levels of individual EDCs in specimens from 
boys with cryptorchidism and from women suffering from breast cancer and their 
respective controls did not become apparent. It appears that the likelihood of developing 
any of the above conditions cannot be attributed to any individual chemical at relevant 
exposure levels. However, there are signs that simultaneous exposure to many different 
EDCs may play a cumulative role in these disease processes. This means that efforts to 
develop biomarkers of cumulative EDC exposure should be re-doubled. In contrast, 
symptoms of endocrine disruption in fish could be explained largely in terms of exposure 
to estrogenic chemicals, but the possible role of antiandrogenic chemicals in disrupting 
sexual development in fish requires urgent attention. Fish caught in certain Dutch rivers 
exceeded the EU permissible levels for polychlorinated dioxins and furans.  
 
Considerable progress has been made in establishing relevant modes of action of EDCs 
and in assessing new endpoints. The screening for EDCs, with its focus on steroid 
receptor interactions, has not kept up with the progress made in understanding rapid 
cellular signalling events that occur in the wake of receptor activation. In the interest of 
avoiding overlooking endocrine active agents it is necessary to expand screening tools to 
capture rapid signalling events. Substantial progress has been also achieved in 
characterising the role of the aromatase system in fish as a target of EDCs and the 
consequences of steroid synthesis disruption on sexual differentiation, reproduction as 
well as non-reproductive processes such as neurodifferentiation. Extensive investigations 
of the role of certain phthalates in disrupting male sexual development have revealed 
delays in germ cell differentiation and other molecular effects as key events underlying 
the induction of the testicular dysgenesis syndrome. The role of the InsL3 protein in 
promoting male sexual development proved to be more complex than thought previously. 
Although the development and validation of an assay for the measurement of InsL3 blood 
levels was successful, the differences in blood InsL3 levels in normal and cryptorchid 
boys were too small to exploit InsL3 as a biomarker indicative of disruption of testis 
descent. The hypothalamic pituitary unit proved to be exquisitely sensitive to the effects 
of several EDCs, and the effects may account for precocious sexual development 
observed after early EDC exposure. EDEN has advanced the study of endocrine 
disruption in fish with activities including the development of microarrays for assessing 
endocrine disruption in zebrafish and establishing sensitive screening tools for endocrine 
disruption in fish. The development of a transgenic fish model for the detection of EDC 
effects proved to be technically too demanding to be completed in time, but efforts 
continue to complete this project after conclusion of EDEN. An in vivo model in fish (the 
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three-spined stickleback) for the detection of antiandrogenic EDC was developed as a 
complement to the Hershberger assay.  
 
Male reproductive health in Denmark and Finland showed a worrying declining trend. 
For the first time, it could be established that the same is true for young men in Germany. 
It is of concern that semen quality among young Germans is similar to the values found in 
young Danes, a group previously thought to show the lowest semen quality in Europe. 
Foetal exposure to smoking has been identified as one reason for these effects. 
Observations of a declining total natural conception rate among the young Danish cohorts 
imply that the current poor semen quality has an impact on the population fertility in the 
future – a situation which will be difficult to reverse in the short term. The current and 
projected widespread use of assisted reproductive technologies may be a sign of such an 
emerging public health problem which also adds to the load of medical costs in young 
population. It is of vital importance to continue surveillance of semen quality and all 
efforts should be made to identify the factors that may cause harm in order to prevent 
further deterioration. 
 
Extensive low-dose studies with EDCs have shown that the conventional estimation of 
no-observed-adverse-effect-levels (NOAEL), with their reliance on hypothesis testing 
methods is inadequate for capturing low-dose effects of EDCs. Whenever possible, 
regression-based approaches with benchmark dose limits should replace NOAEL as the 
basis for establishing acceptable human exposure levels. A framework was developed to 
combine the strengths of both methodologies by making considerations of statistical 
detection limits and statistical power the starting point of testing procedures. 
Implementation of this framework will require a significant change in toxicological 
testing practice.  
 
Determinants of additivity for EDC mixtures have been characterised and are now well 
understood for combinations of similarly acting EDCs. Experimental studies have 
produced evidence that EDCs of relatively low potency and at low exposure levels can 
still work together to produce significant combination effects when they are present in 
sufficient numbers. The perceived low potency of many EDCs alone is uninformative in 
anticipating possible risks stemming from these chemicals. Where EDCs act in concert 
with endogenous hormones, significant additional effects may result under certain 
circumstances. Uncertainty still exists in relation to the likelihood of synergistic mixture 
effects, and concerted efforts should be made to fill this gap. Another source of 
uncertainty that will hamper sound EDC mixture risk assessment is incomplete 
knowledge about the identity of EDCs, their exposure levels and number. This issue can 
only be resolved through the development of dedicated exposure assessment strategies 
that take account of cumulative exposures. Despite these uncertainties, knowledge about 
determinants and factors that govern the joint action of similarly acting EDCs is now 
sufficiently advanced to come to pragmatic risk assessment approaches that take mixture 
effects into consideration. A modus operandi for EDC mixtures was developed which 
includes the use of dose addition (including the toxic equivalency factor approach) to 
arrive at a “mixture no-observed-adverse-effect-level” (MNOAEL) for endpoints relevant 
to endocrine disruption. These are then combined with a safety factor to arrive at 
estimates of tolerable human exposure. “Data-poor” situations may require estimation of 
a crude MNOAEL by dividing individual NOAEL of certain prototype chemicals by the 
anticipated number of relevant similarly acting chemicals. 
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PCDD/F Polychlorinated dioxins and furan 
PND Postnatal day 
POPs Persistent organic pollutants 
SC Sertoli cell 
SHBG Sex hormone-binding globulin 
TDS Testicular dysgenesis syndrome 
TEF Toxic equivalency factor 
TEXB Total effective xenoestrogen burden 
TNCR Total natural conception rate 
VTG Vitellogenin 
YES/YAS Yeast estrogen/androgen screens 
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INTRODUCTION 
 
The EDEN project is an interdisciplinary effort conceived to address key issues that have 
hampered sound hazard and risk assessment for endocrine disrupting chemicals (EDCs) 
in the European Union (EU). It has adopted an approach that fully integrates human, 
wildlife, exposures, mechanisms and low-dose/mixture evaluations. 
 
The EDEN project was structured into four parallel strands of work that centred on 
strongly inter-linked key issues (Figure 1): 
 
• Complex EDC mixtures in human and fish tissues (Theme 1) 
• Mechanisms of EDC action and novel endpoints and biomarkers (Theme 2) 
• Indicators of impaired reproductive function in Europe (Theme 3) 
• Low-dose and mixture effects of EDC (Theme 4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Four interlinking themes comprising EDEN 
 
Complex EDC Mixtures in Human and Fish Tissues (Theme 1) 
Humans and wildlife are exposed to a large number of EDCs, often individually present 
at low levels. Numerous measurements of individual chemicals in human tissues and 
environmental media have been documented (WHO, 2002) but comparatively little 
information is available on the cumulative occurrence of EDCs. However, to facilitate 
better assessments of the impact of EDC it is essential to carry out cumulative exposure 
assessment that provide a global view on many divergent and seemingly unconnected 
groups of chemicals. One aim of EDEN was to produce the foundations of better EDC 
exposure assessments by taking account of cumulative exposures. To realise this aim, 
specimens of human and fish adipose tissue and of fish bile were collected and analysed. 
These tissues were chosen because they are sinks for numerous EDCs. 
 
Specimens from humans and fish with and without symptoms indicative of endocrine 
disruption were compared. In humans, this included samples from boys suffering from 
cryptorchidism, and fish with elevated levels of the egg yolk protein vitellogenin (VTG) 
Theme 2 
 
Mechanisms of EDC action, novel 
endpoints and biomarkers 
Theme 3 
 
Indicators of impaired reproductive 
function in European men 
Theme 4 
 
Low-dose and mixture effects of EDC. 
Providing empirical evidence and 
exploring implications for regulation and 
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Theme 1 
 
Complex EDC mixtures in human and 
fish tissues-exposure assessment 
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and with an intersex status, ovotestes. However, the aim of these studies was not to 
produce evidence that would allow inferences about factors at play during the genesis of 
these conditions. Much larger samples than could be realised in EDEN would have been 
necessary for such studies. Rather, the primary intention of EDEN was to gain an 
impression of the spectrum of EDCs that can be found in tissue specimens. Possible 
differences in the chemicals found in tissues from subjects with and without symptoms 
would develop leads for further studies. 
 
Chemical analyses are essential in exposure assessment, but used alone there is a risk of 
overlooking agents that may also contributing to the overall load of EDCs. It was 
therefore necessary to take a global view on EDCs by making efforts to search for further, 
previously unrecognised EDCs. In the environmental arena, this issue has been tackled by 
using bioassay-directed fractionations of samples representative of complex mixtures. For 
example, extracts of sewage treatment effluents have been fractionated and the fractions 
interrogated with an in vivo assay for estrogenicity, the yeast estrogen screen (YES) 
(Desbrow et al., 1998). This approach revealed the presence of steroidal estrogens, some 
of their conversion products and to a lesser degree, alkylphenols as contributing to the 
total estrogenic load in waste waters. However, human tissue samples have not been 
subjected to similar analyses, nor have other assays representative of EDC action been 
widely used in such studies. The EDEN project set out to fill this gap by analysing 
extracts from human tissues. Furthermore, attempts were made to analyse one and the 
same fractionated extracts with a battery of in vitro assays, including one for inhibition of 
a steroid metabolising enzyme, estrogen sulfotransferase.   
 
Mechanisms of EDC Action and Novel Endpoints and Biomarkers 
(Theme 2) 
A wide variety of assays are available for the identification and hazard characterisation of 
EDCs, ranging from in vitro assays to multi-generational and full life-cycle test (see for 
example OECD 2002). Nevertheless, EDC testing and screening faces a dilemma: Given 
that many EDCs act during specific developmental periods, an identification of the entire 
spectrum of EDC effects would require multi-generational studies and full life-cycle 
testing. However, to subject every suspect chemical to such exhaustive testing is not 
sustainable because it is extremely time consuming and cost intensive. In contrast, most 
of the available in vitro and in vivo screening assays for EDCs can be conducted rapidly, 
but they only encapsulate interactions with the estrogen, androgen and thyroid receptors 
and consequent down-stream events. Although positive test outcomes indicate the 
potential for endocrine disruption, the relevance of screening endpoints for risk 
assessment is often unclear: 
 
For example, key processes of male sexual differentiation are regulated by the androgen 
receptor, and after in utero exposure, androgen receptor antagonists may lead to 
feminising effects among male offspring. However, not all androgen receptor antagonists 
identified in in vitro screens are capable of inducing such effects in vivo. At the time the 
EDEN project was conceived, there were suggestions that the spectrum of effects seen as 
a result of disruption of male sexual differentiation in rodent models (retained nipples, 
reduced anogenital distance etc) is distinct from testicular dysgenesis (misplaced Leydig 
cells, seminiferous tubules without gonocytes, etc), a condition of relevance to the human. 
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Thus, it was essential to further the understanding of the processes leading to the 
testicular dysgenesis syndrome (TDS) in the human. 
  
Similar problems exist with the interpretation of positive results from estrogenicity 
screening, both in vitro and in vivo. The concern is that estrogens may contribute to breast 
cancer risks, but they also play a role in normal breast development. Although perhaps 
indicative of a potential for endocrine effects, it is difficult to equate estrogen receptor 
(ER) activation as such with adversity. 
 
It is also unclear whether the appearance of ovotestes in fish is a phenomenon mediated 
by ER activation, or whether other processes such as antiandrogenicity, play a role 
(Jobling et al., 2005), thus complicating the interpretation of positive results from 
estrogen screening assays. 
 
Aromatase cyp19 is an enzyme which converts androgens into estrogens, thus being the 
regulator of estrogen levels in the organism. Prediction of multiple transcription 
regulatory sites in the promoters of teleost aromatases suggested the sensitivity of this 
system to several EDC classes - a hypothesis that needed testing. More information was 
needed on the functional aspects of aromatase in fish as well. 
 
EDEN has responded to some of these issues by conducting detailed research into the 
mechanisms that underlie EDC action. The focus was on the regulation of estrogen-
dependent genes, on the mechanisms leading to TDS in humans, on searching for 
biomarkers predictive of male reproductive disorders such as cryptorchidism and on 
novel in vivo assays for the identification of antiandrogens. 
 
Indicators of Impaired Male Reproductive Function (Theme 3) 
In male adults, malformations that can be diagnosed shortly after birth (cryptorchidism, 
hypospadias) are predictive of poor semen quality and testis cancer risk later in life. 
Collectively, these conditions make up a cluster of disorders termed TDS (Skakkebæk et 
al., 2001). During the last 5-7 years a number of studies have been carried out in different 
European countries (Andersen et al., 2000; Jørgensen et al., 2002; Jørgensen et al., 2006; 
Punjab et al., 2002; Richtoff et al., 2002) which revealed large regional differences in 
semen quality and the incidence of congenital malformations within Europe. 
 
Consequences of disturbed Leydig cell function 
In the past, poor reproductive health in men has mainly been explained in terms of 
disturbed Sertoli cell (SC) function. Compromised SC function is thought to lead to 
reductions in semen quality and development of testicular cancer (Skakkebæk et al., 
2001). Less attention has been given to the possible adverse effects of reductions in 
Leydig cell (LC) function. Disturbed LC function may have distinct effects on male 
reproductive health - mainly through altered testosterone production. Testosterone plays a 
key role in the development of the external male genitalia, and in the adult men drives 
spermatogenesis and libido. Longitudinal studies have shown a general decline of serum 
testosterone levels with age (Feldman et al., 2002; Morley et al., 1997) indicating a 
decrease in LC function with advancing age. However, cross-sectional surveys have 
demonstrated very different rates of decline, some even showing no decrease in 
testosterone levels with increasing age (Deslypere and Vermeulen, 1984; Drafta et al., 
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1982; Gray et al., 1991; Gyllenborg et al., 2001; Nieschlag et al., 1982; Simon et al., 
1992; Svartberg et al., 2003). This discrepancy in the age related decline in serum 
testosterone between cross-sectional and longitudinal studies might be due to confounders 
such as secular or cohort effects on hormone levels, which may hide or blunt the effect of 
aging. The EDEN project set out to investigate whether there has been a population level 
decline in male serum testosterone over the last decades. 
 
Declines in semen quality in Central Europe 
One of the first observations suggesting deteriorating male reproductive health was an 
apparent decline in sperm numbers of normal men reported 15 years ago (Carlsen et al., 
1992). After that meta-analysis it became obvious that prospective and international 
multi-centre studies are needed to assess temporal and regional differences in semen 
quality. It was soon found that there were rather large geographical differences in semen 
quality, and Finland was clearly contrasting Denmark with a better semen quality. On the 
other hand, very few data were available from Germany. The marked differences in 
industrial activities in East and West Germany after the Second World War offered the 
opportunity to investigate whether this had had any influence on semen quality. Thus, the 
objective was to expand an existing Scandinavian research database with data on clinical 
findings, semen quality, hormone levels, lifestyle factors and exposures to include also 
data on male reproductive health in the former East and West Germany. 
 
Low-dose and Mixture Effects of EDCs (Theme 4) 
The endocrine disrupter “low-dose” issue 
There are claims that some EDC-mediated effects occur at dose levels lower than 
normally tested in toxicology (vom Saal and Hughes 2005). However, researchers have 
encountered difficulties in reproducing these “low-dose” claims (Ashby et al., 2004) and 
this has provoked an unusually heated debate in the field.  
 
Despite these disputes, observations of low-dose effects, coupled with non-monotonic 
dose-response curves continue to appear. A recent example is the estrogenic UV filter 
substance 3-benzylidene camphor which induces increased embryo production in aquatic 
snails at low, but not at high doses (Schlumpf et al., 2004). An explanation for such 
effects may lie in dose-dependent changes in the mode of action of the chemical, such 
that estrogenic effects are masked by toxicity at higher doses. Similar conclusions have 
been drawn from experiments with phytoestrogens (Almstrup et al., 2002). Thus, do EDC 
have special properties, in terms of their ability to induce effects at low-doses that 
disappear as doses are raised? Is there a danger of overlooking such effects during 
standard toxicity testing which is carried out at higher doses? 
 
While these questions have attracted considerable attention in the endocrine disrupter 
field, another, less widely debated, perspective on the low-dose problem has emerged: 
Large-scale studies involving turtle eggs have suggested that EDCs may not exhibit effect 
thresholds when acting in concert with endogenous hormones (Shehan et al., 1999). It has 
been argued that in such situations every quantum of external exposure will lead to 
additional effects, even if exposure is infinitesimally small. 
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The EDEN project has addressed these issues by assessing whether unusually shaped 
dose-response curves occur in a wide variety of assay systems relevant to EDC testing. 
Inevitably, this has made it necessary to confront the general problems that exist in 
estimating low-doses experimentally. For this reason, a second aim of the EDEN project 
has been to compare numerical low-dose estimates which were generated by employing 
two approaches currently used for the estimation of “safe” doses: hypothesis testing 
methods which arrive at no-observed-effect-levels (NOEL) and regression-based 
methodologies which yield so-called benchmark doses. 
 
Mixture effects 
EU chemicals risk assessment is carried out by dealing with single chemicals in isolation. 
The process does not take account of the possibility that combination effects might occur 
when humans or wildlife come into contact with several agents simultaneously. 
Considering that there are 30,000 – 50,000 chemicals marketed in the EU, with an 
estimated 50,000 chemicals present in surface waters (Matthiessen and Johnson 2007) 
and an unknown number prevalent in human tissues, the general potential for mixture 
effects is considerable, even if only a fraction of these chemicals have endocrine 
disrupting potential. 
 
At the time the EDEN project was drawn up, comparatively little was known about EDC 
mixture effects. There was an emphasis on demonstrating synergistic effects, but when 
early reports of strong synergisms between estrogenic pesticides (Arnold et al., 1996) 
could not be confirmed, the relevance of EDC mixture effects was called into question. 
However, given that exposure to EDCs may involve a large number of chemicals, even 
additivity is of concern. A key issue in risk assessment is whether combination effects 
with EDCs occur even when each individual chemical is present at low, ineffective 
exposure levels. 
 
First multi-component mixture experiments conducted with in vitro assays showed that 
EDC acted together in an additive fashion (Payne et al., 2000, 2001). While these studies 
were helpful in demonstrating principles, no data existed from in vivo assays with 
endpoints of toxicological relevance. There was great uncertainty whether in vivo 
endpoints would be sufficiently reproducible to be useful in experiments involving multi-
component mixtures. Finally, information was missing about EDC mixture effects at 
environmentally relevant concentrations. 
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THEME 1 - COMPLEX EDC MIXTURES IN HUMAN AND 
FISH TISSUES 
 
Overview and Objectives 
EDEN has made a systematic attempt to analyse a wide range of multiple EDCs to gain 
an impression of the spectrum of contaminants simultaneously present in human and 
wildlife tissues. This has been achieved not only by analysing a wide range of multiple 
EDCs chemically, but also by newly developed high information content bioassays in 
order to characterise and profile low level exposures and effects of EDCs. Putative 
correlations between internal exposures derived from chemical analyses and conditions 
indicative of endocrine disruption have been integratively investigated. Using bioassay-
directed fractionation, correlations have been made as well between measures of total 
EDC activity and chemicals analysed. With this new integrative strategy, this theme has 
provided new tools and insights into risk assessment procedures for low level mixture 
exposures of wildlife and humans. The specific objectives were to: 
 
• Provide information on the spectrum of known EDCs in human and fish tissues. 
• Search for new EDCs in human and fish sample extracts. 
• Explore the usefulness of measures of total (anti)estrogenicity, (anti)androgenicity 
and estrogen sulfotransferase inhibition as predictors of unwanted outcomes in 
human and fish. 
• Evaluate EDC bioassays for their suitability for bioassay-directed fractionations. 
 
Materials and Methods 
Adipose tissue samples from boys with undescended testes (cryptorchidism) and their 
controls (boys undergoing hernia operation or other abdominal surgery) were collected in 
Denmark (13:10, case:control) and Finland (35:30, case:control). Adipose tissue samples 
from ten breast cancer patients and ten women not suffering from breast cancer were 
collected in Spain. An additional 35 adipose tissue samples obtained from women in 
Southern Spain were provided for further chemical analyses. This data set is unique because 
it also involved the follow up of women who had undergone major surgery for breast cancer. 
Three successive tissue samples were obtained in an 18 month follow up period. 
 
The bream (Abramis brama) was chosen as a fish species for tissue sampling as it occurs 
widely in European rivers. Analysis of pooled bile and adipose fat samples was based on 
fish sampled from the Dutch river Biesbosch stratified according to high VTG versus low 
VTG levels. Samples from the Dutch rivers Aa and Dommel were separated into fish with 
ovotestis, a condition indicative of early life stage exposure to EDC where male 
reproductive tissue is interspersed with female tissues - and fish with normal reproductive 
tissues. Of the captured bream, a large fraction (64-100%) showed elevated VTG levels 
which correlated to sewage effluent discharges into rivers. Ovotestes were less commonly 
found; in the river Aa 9 males (16%) showed ovotestis, whilst at the other impacted sites 
only two males with ovotestes were found. The selected fish in each set were of the same 
age. 
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All collected samples (human and fish) were analysed with GC/MS or LC/MS/MS for the 
following EDCs: Organochlorine pesticides (17 chemicals), bisphenol (Bisphenol A and 4 
chlorinated derivatives), alkylphenols (2 chemicals), steroidal estrogens (4 chemicals), 
phytoestrogens, parabens (3 chemicals), phthalate monoesters (8 chemicals), or with 
GC/HRMS for polychlorinated dioxins and furans (PCDD/Fs) (17 congeners), 
polychlorinated biphenyls (PCBs) (37 congeners), polybrominated biphenyls (PBBs) (19 
congeners), polybrominated diphenyl ethers (PBDEs) (14 congeners), and HO-PCBs 
according to methods described earlier (Kiviranta et al., 2002; Isosaari et al., 2006; 
Fernandez et al., 2006). 
 
A new method for the analysis of phthalate monoesters in fish muscle has been developed 
and validated. Briefly, the method involves liquid extraction followed by 2 solid phase 
extractions with determination on LC/MS/MS. Fish tissue was extracted with ethyl 
acetate: cyclohexane (95:5) as described in detail for breast milk and placenta samples 
(Mortensen et al., 2005). C-13 labelled monoesters were used as internal standards and 
added to all samples. For recovery experiments native standards were added to the 
sample.  
 
For assessing the (anti)estrogenicity and (anti)androgenicity, adipose tissues from fish 
and humans and fish bile extracts underwent accelerated solvent extraction, liquid/liquid 
extraction or solid phase extraction (bile). The extracts were fractionated by using liquid 
chromatography and tested using a battery of in vitro assays, E- and A-Screen, yeast 
estrogen/androgen screens (YES/YAS), ER high resolution screening (HRS) technology 
combined with mass spectrometry and the human estrogen sulfotransferase (hEST) 
inhibition assay.  
 
For bioassay directed fractionations, the total effective xenobiotic burden (TEXB) method 
extracts and separates the more lipophilic compounds (alpha fraction) from ovarian 
estrogens and most polar compounds (beta fraction). The alpha fraction was then 
examined in a bioassay (E- and A-Screen) for determination of the cumulative effect of 
the EDCs.  
 
Results 
Human and fish tissue samples collected as a part of EDEN were analysed for nearly 150 
different EDCs. These analyses showed that a large number of EDCs occur together in 
human and fish tissue. 
 
Considering single chemicals in human tissues, no differences were identified between 
the specimens collected from diseased subjects (breast cancer, cryptorchidism) and those 
without endocrine-related conditions. This may be due to two factors: (1) Many of the 
analytes are highly lipophilic and can accumulate through food chains. As a result, they 
occur everywhere, with the consequence that subjects free of these pollutants cannot be 
found. (2) The number of samples that could be collected for EDEN was too small to 
afford the statistical power that is needed to detect differences, if they exist. Even so, 
there were certain noteworthy trends: 
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Levels of EDCs in boys are similar to those found in adults 
The small quantities of adipose tissue that could be obtained from cryptorchid boys and 
boys undergoing hernia operations did not permit analyses of a large spectrum of 
different EDCs. Instead, analytical work had to focus on persistent organic pollutants 
(POPs) only; the choice of POPs was based on results from another EU project 
(EXPORED). It was found that the body burden of POPs in boys can easily reach levels 
similar to those measured in adults (Kiviranta et al., 2005), likely as a consequence of 
exposure during the prenatal period and following lactation. The exposure data for EDCs 
in infants or very young children makes this study invaluable as little information is 
currently available worldwide. 
 
POP profiles in cryptorchid boys from Denmark differed from those in Finland 
An evaluation of the profiles of POPs in the tissues obtained from Danish and Finnish 
cryptorchid boys revealed interesting differences between the countries. The percentage 
profile of PCDD/F congeners from the sum of PCDD/Fs as well as percentages of each 
congener from WHOPCDD/F-TEQs showed that boys in Denmark are more exposed to 
congeners with the highest toxic potency (2,3,7,8-TCDD, 1,2,3,7,8-PeCDD, and 
2,3,4,7,8-PeCDF). Similarly, the percentage profiles for PCB and PBDEs indicated that 
boys in Denmark were more exposed to congeners with a higher degree of 
chlorination/bromination (Table 1). However, certain confounders must be addressed in 
order to confirm the validity of these findings (e.g. age of each child when operated, 
lactation history). 
 
Table 1 Concentrations of sums of PCDD/Fs (17 congeners), PCBs (37 congeners), and 
PBDEs (14 congeners) as well as toxic equivalents of PCDD/Fs 
(WHOPCDD/F-TEQ) and PCBs (WHOPCB-TEQ) in adipose tissue of 
cryptorchid boys from Denmark and Finland. 
 
Country 
 
PCDD/F 
pg/g 
Mean (Stdev) 
Median 
Maximum 
PCB 
ng/g 
Mean (Stdev) 
Median 
Maximum 
PBDE 
ng/g 
Mean (Stdev) 
Median 
Maximum 
WHO-PCDD/F-TEQ 
pg/g 
Mean (Stdev) 
Median 
Maximum 
WHO-PCB-TEQ 
pg/g 
Mean (Stdev) 
Median 
Maximum 
Denmark 74.9 (63.4) 203 (168) 5.4 (5.7) 8.7 (8.4) 7.8 (6.4) 
 67.7 167 4.1 8.8 6.8 
 248 697 30.3 27.9 27.9 
Finland 125 (168) 136 (146) 11.5 (16.5) 7.8 (10.5) 5.5 (6.2) 
 87.8 79.5 5.7 3.6 2.6 
 1,270 600 85.3 48.6 31.1 
 
Differential occurrence of EDC in fish showing signs of endocrine disruption 
In contrast to the human samples, it was found that certain EDCs occurred at higher levels 
in tissues from some fish that showed signs of endocrine disruption. Notable were 
elevated levels of octylphenol in fish with ovotestes from the Dutch river Aa. Similarly, 
concentrations of the estradiol conversion product estrone (E1), and of the contraceptive 
pill ingredient 17α-ethinylestradiol (EE2) were significantly higher in fish with ovotestes 
compared with those that did not show this condition (Figure 2). However, the bile of fish 
with signs of recent exposure to estrogens, as judged by their VTG levels, did not show 
any differences in terms of steroid concentrations.  
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For a large number of predominantly lipophilic EDCs, including organochlorine 
pesticides such as o,p’-DDT, aldrin, dieldrin, HCB, lindane or endosulfan, statistically 
significant differences in fish with ovotestes and their controls, or those with elevated 
VTG and controls, could not be detected. 
0
50
100
150
200
250
Fu
lle
xt
ra
ct
Fr
ac
tio
n 
6
Fu
lle
xt
ra
ct
Fr
ac
tio
n 
6
Fu
lle
xt
ra
ct
Fr
ac
tio
n 
6
Estron Estradiol Ethinylestradiol 
ng
 / 
m
l b
ile Ovotestis
OvoControl
Biesb high
Biesb low
 
Figure 2 Concentrations of estrone, 17β-estradiol and 17α-ethinylestradiol in 1ml 
bile of bream from Dutch rivers. Shown are the results from two pools of 
fish: One stratified according to the presence of ovotestes (red/orange), the 
other according to the levels of VTG (high vs low) in the river Biesbosh 
(dark green/light green). For quality control reasons, the steroid levels found 
in the full extract were compared with those in the chromatographic fraction 
(Fraction 6) where the steroids elute. 
 
The newly developed analytical method for phthalates in fish muscle was used to screen 
the fish. Of all the phthalates and their monoester breakdown products analysed, only 
mBP and mEHP were detected in fish. There were no significant differences in the levels 
of mBP and mEHP in muscle from fish with ovotestis and age-matched controls, neither 
when analysed for each different catch site nor for all three catch sites combined (Mann-
Whitney test). The levels of mBP and mEHP in muscle from fish from the three catch 
sites Dommel, Aa and Biesbosh did not differ significantly (Table 2).  
 
Table 2 Median levels of phthalate breakdown products in fish muscle from Dutch 
rivers. Ranges are shown in parentheses. 
 
(µg/kg) Dommel (n=6) 
Aa 
(n=27) 
Biesbosh 
(n=6) P
* 
mBP 9.3 (6.7-11.0) 7.7 (2.5 – 15.0) 8.4 (2.9 – 13.0) 0.46 
mEHP 10.4 (5.1-32.0) 9.8 (3.1 – 89.0) 5.9 (3.4 – 9.9) 0.14 
*Kruskal-Wallis test 
 
Pollution levels of PCBs and PCDD/F in fish from the Dutch Biesbosch river exceed 
EU maximum permissible limits for fish meat 
The levels of PCBs and PCDD/F that were found in the adipose tissues of Dutch fish 
revealed striking differences. The levels found in the rivers Biesbosh and Dommel were 
consistently higher than those in fish from the Aa. The PCDD/F and PCB levels in the 
** **
n = 3
** **
 
Case: Ovotestis 
Control: No ovotestis 
Case: High vitellogenin 
Control: Low vitellogenin 
strone Estradiol t i lestradiol
    22 
 
 
EDEN Final Report  QLK4-CT2002-00603 
river Dommel and the river Biesbosch were elevated with the WHOPCDD/F-PCB-TEQ 
concentrations (17-53 pg WHOPCDD/F-PCB-TEQ/g fresh weight) exceeding the EU maximum 
limit value (8 pg WHOPCDD/F-PCB-TEQ/g fresh weight) by three-fold an average (OJEU, 
2006). The case for PCDD/F-TEQ levels in fish is illustrated in Figure 3.  
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Figure 3 Median (and range) WHOPCDD/F-TEQs in bream samples from different rivers 
in the Netherlands. The ages of the fish (ranges in parentheses) are shown 
below the bars. The dark blue bars are data from fish with ovotestes (Aa and 
Dommel) or with elevated VTG levels (Biesbosch), the light blue bars are 
from fish without any signs of EDC-related effects. 
 
The fresh weight concentrations of flame retardants PBDEs in bream from the river Dommel 
were four times as high as levels in the other two rivers showing that river Dommel is clearly 
more polluted with those chemicals when compared with the other two rivers (Figure 4). 
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Figure 4 Sum of PBDEs in bream from Dutch rivers. Shown are median levels and 
their range (error bars). Numbers below bars are median ages of the fish and 
their range in parentheses. The black bars are data from fish with ovotestes 
(Aa and Dommel) or with elevated VTG levels (Biesbosch), the white bars 
are from fish without any signs of EDC-related effects. 
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Suitability of bioassays for bioassay-directed fractionation 
A factor complicating the use of bioassays for bioassay-directed fractionations is toxicity 
arising from unidentified chemicals which may interfere with the assay and potentially 
mask biological effects arising from specific groups of chemicals which the assay is 
designed to respond to. Thus, it was important to assess the suitability of a variety of 
assays for bioassay-directed fractionations of complex mixtures from human and 
environmental samples. In order to determine the estrogenicity of human and fish samples 
following extraction and fractionation (high performance liquid chromatography - HPLC) 
the following assays were evaluated: 
 
• MCF-7 breast cancer cell proliferation assay (E-Screen) 
• YES, a reporter gene assay based on beta galactosidase 
• HRS coumestrol-based ER affinity detection (HRS-ERα RAD) assay 
•  A HRS-androgen receptor affinity detection (HRS-AR RAD) assay was also 
undertaken, but too low expression levels of the androgen receptor necessitated 
postponement of ligand synthesis. 
 
Both the E-Screen and YES bioassays are widely used for assessing estrogenicity. In 
general, similar responses were observed, however for the adipose tissues from fish with 
ovotestis, the E-Screen determined higher estrogenicity (~6.51 ng/g fat) than the YES 
(<LOQ = 1.08 ng/g fat). Possible reasons may be the different extraction methods which 
did not remove all agents that may inhibit the bioassays or the fact that the E-Screen also 
allows for stimulation of cell proliferation via cell signalling pathways not present in the 
YES. All chemicals were present at concentrations very close to the detection limits and 
with the small sample size concentration of the sample was not an option. In addition to 
the E-Screen and YES bioassays, two further bioassays were developed and evaluated.  
 
A new bioassay called the hEST assay was developed and optimised to screen samples 
for unknown/new hEST-inhibitors. The substrate 1-hydroxy-pyrene is mixed with hEST 
which converts 1-hydroxy-pyrene into 1-sulphate-pyrene, a product which can be 
measured on HPLC with fluorescence detection. hEST inhibitors decrease the hEST-
mediated product formation. 
 
The HPLC-based hEST bioassay was applied to pooled fish bile samples and differences 
between the ovotestis cases and controls and the VTG cases and controls were observed. 
In particular, the ovotestis cases showed greater inhibition compared to the VTG cases 
and controls. However, the overall trend for inhibition in all case and control fractions 
was similar with high inhibition identified in Fractions 5-9 inclusive (Figure 5). EDCs 
correlating to these fractions are BPA and steroidal estrogens in Fraction 6 and 
nonylphenol in Fraction 8, with more polar compounds containing more hydroxyl or even 
acidic groups eluting prior to the Fraction 6. Whereas the YES found Fraction 6, to be 
responsible for all the estrogenicity identified in the fish bile samples, the hEST inhibition 
assay shows additional fractions possessing similar inhibition to that of Fraction 6 and 
determining the causative chemicals for this inhibition is for future study.  
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Figure 5 Results from the hEST inhibition screening of 10 fractions and the full 
extract from bile of bream from the pooled samples of two case/control 
studies: high versus low VTG levels and ovotestis versus normal fish. 
 
Another bioassay called the coumestrol-based HRS ERα system was developed and applied. 
The HRS system consists of a HPLC system coupled on-line to an ERα bioaffinity detection 
system where an ERα ligand binding domain (LBD) is continuously mixed with coumestrol 
which shows fluorescence enhancement upon binding to the ERα LBD. With the HRS 
individual ERα binding components in mixtures can be identified. The detection limits for 
the ERα-binding response are strongly dependent of the intrinsic ERα-affinities of the 
individual components. The HRS ERα assay worked well: like the YES assay the HRS 
assay detected E1, 17β-estradiol (E2) and EE2 in fish bile samples. However, the HRS-
assay appeared not suitable to detect low level EDCs with too low affinity for ERα and 
thus this assay was found not suitable for bioassay directed fractionation. 
 
Novel EDCs were not identified by using bioassay-directed fractionations 
In general, novel, previously unidentified EDC were not found in human or fish tissue 
samples. The use of in vitro estrogenicity assays on tissue extracts revealed significant 
estrogenicity, but correlations between the concentration of any single chemical or group 
of chemicals and the estrogenicity determined by the E-Screen bioassay could not be 
detected. However, in the multivariate analysis, both individual chemical residues and the 
estrogenicity of individual eluted fractions predicted the estrogenicity of the mixture with 
high accuracy. 
 
Steroidal estrogens were largely responsible for the estrogenicity found in fish 
tissues 
A different extraction methodology followed by a 10 part fractionation was applied to the 
pooled fish bile samples and then assessed with the YES and HRS assays. With the YES 
assay, the estrogenicity as estradiol equivalents (EEQs) was determined in the full extract 
and Fraction 6 which corresponded to elution of the steroid estrogens. Comparison of the 
two gave similar estrogenic responses, especially for the two cases, VTG and ovotestis 
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(Figure 6). The estrogenicity in the bile could be entirely explained by the steroid 
hormones E1, E2 and EE2.  
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Figure 6 Comparison of the estrogenicity as measured by using the YES in 1 ml of 
bile for the full extract and Fraction 6 which corresponds to steroid estrogen 
elution [VTG; vitellogenin]. 
 
A significantly higher concentration of E1 and EE2 was found in the bile of the fish with 
ovotestis compared to those fish without ovotestis. Steroid concentrations were lower in 
the VTG case/controls than the ovotestis case/controls. No significant difference was 
found in estrogenicity or steroid concentrations between the fish with high and low 
plasma VTG levels.  
 
Discussion 
The EDEN project has made a concerted effort to analyse an array of nearly 150 EDCs 
from the same tissue samples, and this has revealed that numerous EDCs occur together 
in humans and fish. However, differences in the levels of individual EDCs in specimens 
from cryptorchid boys and from women suffering from breast cancer and their respective 
controls did not become apparent. Considering the size of the samples accessible to the 
EDEN project, and the ubiquitous character of the chemicals analysed this is not 
surprising. It appears that the likelihood of developing any of the above conditions cannot 
be attributed to any individual chemicals. On the other hand, there are signs that 
simultaneous exposure to many different EDCs may play a cumulative role. For example, 
Olea and associates (Ibarluzea et al., 2004) have found significant associations between 
total xenoestrogenic load in blood serum and risk of breast cancer, and similar findings 
were made with estrogenicity in placenta and risk of cryptorchidism and hypospadias in 
young boys (Fernandez et al., 2007). This means, that further efforts are required to 
develop meaningful biomarkers of EDC exposure that can encapsulate its cumulative 
nature. 
    
In fish, signs of endocrine disruption could be attributed to exposure to steroidal 
estrogens, and in some cases there were elevations in certain alkylphenol levels. In 
general however, the picture emerging from analyses of the fish samples echoes that of 
the human situation: apart from steroidal estrogens, individual chemicals cannot be 
n = 3
Case 
Ovotestis 
Control 
Low VTG 
Case 
High VTG 
Control 
No ovotestis 
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identified as contributing significantly to endocrine disruption in fish. Again, this can be 
interpreted as demonstrating the need for developing and validating biomarkers 
representative of cumulative exposures. 
 
In both cases, human and fish, the utilisation of bioassays sensitive to cumulations of 
certain classes of EDCs may be the way forward to resolve the issue. 
  
Of concern are observations of elevated, an average three-fold, levels of dioxin-like 
pollutants in fish from certain Dutch rivers when comparing to the EU maximum limit of 8 
pg WHOPCDD/F-PCB-TEQ/g fresh weight). It is advisable that the Dutch authorities investigate 
how widespread this pollution of fish is. 
 
Conclusions 
A wide range of EDCs could be found in human tissues. There is considerable uncertainty 
about the full spectrum of EDCs in humans. Bioassay-directed fractionations producing 
several fractions where effects were observed but no known EDCs are yet attributable for 
these responses. Concerning estrogenic chemicals, the situation is different in fish. Here, 
steroidal estrogens accounted for the majority of estrogenicity found in complex mixtures 
extracted from tissue samples. However, bile extracts showed the ability to strongly 
inhibit hEST, and the identity of the causative inhibitory chemicals is largely unknown.  
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THEME 2 - MECHANISMS OF EDC ACTION AND NOVEL 
ENDPOINTS AND BIOMARKERS 
 
Overview and Objectives 
Although EDCs are suspected of being involved in inducing reproductive health problems 
in humans and wildlife the ways in which these effects are induced are largely unknown. 
To close important knowledge gaps, EDEN carried out studies with the following aims to: 
 
• Further the understanding of the mechanisms of EDC action through identification 
of novel endpoints and biomarkers. 
• Explore foetal exposure of rats to phthalates as a new model for the identification 
of mechanisms underlying the TDS in the human. 
• Examine the validity of using insulin-like factor 3 (InsL3) levels in blood as 
indicator of endocrine disruption leading to male reproductive developmental 
disorders. 
• Investigate the mechanisms that underlie disturbance of the hypothalamic-
pituitary (HP) unit, and examine its biological consequences and relevance to 
man. 
• Develop and utilise a transgenic, translucent fish model, based on the expression 
of the green fluorescent protein (GFP) to assess EDCs. 
• Develop a standard operating procedure for the detection of antiandrogens in vivo 
in a fish model, the stickleback. 
 
Materials and Methods 
Gene expression profiling and cell signalling 
Cultured mammalian cells (MCF-7 human breast cancer cells) were treated with EDC and 
RNA and protein extracts prepared using established procedures. The up- or down-
regulation of certain gene products was assessed by using Western-blotting, and changes 
in mRNA levels were monitored by using real-time RT-PCR. Further, array technologies 
were developed for screening EDC effects in the zebrafish. 
 
Foetal exposure of rats to phthalates 
Studies directed at identifying new biomarkers of phthalate action on the foetal rat testis 
have involved treatment of time mated pregnant rats with daily doses of dibutyl phthalate 
(DBP) varying from 4 to 500 mg/kg/day with the treatment period ranging from embryonal 
day 13.5 (e13.5) to e21.5 (standard regimen used for most studies). In some studies it was 
restricted to particular shorter windows (e13.5-e15.5 or e19.5-e21.5). Exposed male 
offspring have then been sampled at foetal ages ranging from e15.5-e21.5 or postnatally at 
ages ranging from 4-90+ days (adulthood). At each age, testis morphology, cell numbers and 
cell function/maturation have been assessed and at some ages cell proliferation and/or 
apoptotic rates have been determined. 
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In vitro cell screening system of chemicals affecting InsL3 gene expression 
Mouse tumour LCs (mLTC-1) were transfected with a reporter construct containing the 
Insl3 promoter in front of the luciferase reporter gene. This promoter possesses three SF-1 
binding sites which have been shown to be important for regulation of the mouse Insl3 
gene. Transfected cells were used to screen for the effects of E2, testosterone and human 
chorionic gonadotrophin (hCG) on Insl3 gene expression in vitro. mLTC-1 cells were 
seeded in 6-well plate wells in Waymouth’s medium 24h prior to transfections. On the 
following day the transfections were performed in triplicate using 0.5µg, 1.0µg or 1.5µg 
of reporter construct, 0.25µg or 0.05µg mERa/empty construct and 6µl FuGENE6 
transfection reagent per well. The amount of DNA/well was always set equal in every 
experiment by using empty pIRES-EGFP vector as a compensator. The day after the 
medium was replaced with fresh Waymouth’s medium containing foetal calf serum, 
serum stripped of endogenous steroids and different concentrations of E2, testosterone or 
hCG in ethanol or ethanol only as control. Then, 24h after hormone stimulation the cells 
were lysed. The lysates were centrifuged and luciferase activity was measured from the 
supernatants. Tranfection efficiency was measured by co-transfecting the cells with 
Promega’s phRL-SV40 vector that encodes Renilla luciferase. 
 
Development of an ELISA for InsL3 
The assay was built up using: 1. An anti-ratInsl3 antiserum (CR15) generated using 
genetic immunisation of rabbits. 2. A synthetic rat Insl3 peptide supplied by Richard Ivell 
(Adelaide) and Ross Bathgate (Melbourne) as a calibration standard. 3. The same peptide 
labelled with an Europium chelate to give fluorescence signals when used as a tracer to 
compete in the assay with calibration samples or with Insl3 molecules in actual rat blood 
samples, for binding sites on the anti-ratInsl3 antibodies attached to the measuring well. 
In the first experiments the use of antiserum CR15 resulted in disappointingly low 
uncompeted tracer binding (B0) values. Other antibodies were tried, but these turned out 
to lead to even worse values, both in terms of B0 values as well as in terms of sensitivity. 
After optimising buffer and incubation conditions, CR15 finally led to sufficiently high 
B0 values and gave reliable standard curves. The study materials comprised sera from 
normal adult female and male rats (as controls), sera from adult castrated rats, and blood 
samples from EDS-, and DBP- treated male rats. The sera from castrated rats should most 
presumably be free of Insl3 and thus served as blank sera, which were spiked with the 
synthetic calibration standard to generate calibration curves in the same matrix as the 
actual sample. The reliable measuring range for the assay encompassed 5 to 300 pg rat 
Insl3 per 100µl of sample. This was similar to the measuring range of the immunoassay 
for human Insl3. Specificity of the assay was controlled by spiking assay buffer with 
defined amounts of rat Insl3 and related peptides and comparing the respective 
competition curves. Only human Insl3, the closest relative to rat Insl3 in the peptides 
used, showed a slight reduction of tracer binding. Females, castrated and EDS-treated 
male rats (EDS destroys the Insl3-producing LC in the testes) were at the baseline, as 
expected. 
 
Investigations of the sensitivity of the hypothalamic-pituitary (HP) unit to endocrine 
disruption  
To investigate HP sensitivity to endocrine disruption, experimental (rat) studies, 
involving neonatal exposures (i.e., during critical period of brain sex differentiation) to 
different doses of synthetic estrogens, androgens or antiandrogens were conducted, and 
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brain (hypothalamus), pituitary and serum samples obtained at different age points of 
postnatal development. Analytical approaches involved the combination of gene 
expression and hormonal assays. Gene targets were selected on the basis of previous 
knowledge about their pivotal role in the control of key aspects of reproductive function 
as well as on high-throughput screening for differentially expressed genes after selected 
neonatal exposures. Selected gene targets were also screened in hypothalamic and 
pituitary samples from large-scale in vivo mixture experiments. In addition, ex vivo 
models (hypothalamic explants and measurements of gonadotropin releasing hormone –
GnRH-) were used in combination with in vivo exposures to evaluate potential 
mechanisms for precocious activation of the HP unit by EDC compounds, such as DDT. 
The latter might be clinically relevant given the observation of precocious puberty in girls 
from underdeveloped countries migrating to Europe and USA for adoption. 
 
Development of transgenic zebrafish for detecting EDC effects 
A DNA constructs containing the estrogen-responsive promoter ERE coupled to the 
sequence coding for the GFP or different parts of zebrafish aromatase cyp19b promoter 
coupled to EGFP, with or without amplifying sequences, were prepared and injected into 
zebrafish embryos at the one cell stage. These were allowed to develop and were then 
used for breeding experiments. To ascertain successful incorporation of the transgene fish 
from successive generations were monitored. 
 
Results 
Environmental estrogens reveal molecular effect profiles and signalling cross-talk 
that might be missed in current screening exercises  
Detailed investigations during the last few years have uncovered a surprising complexity 
of the mode of action of the sex steroid hormone, E2 and its interactions with the ER. The 
ER functions as ligand-dependent transcription factor which is able to directly regulate 
gene expression by binding to specific DNA sequences, estrogen response elements 
(ERE). In recent years it has become clear that E2 can also rapidly and transiently trigger 
a variety of second messenger signalling events, including the induction of cAMP and 
adenylate cyclase, of Src with consequent activation of the extracellular-regulated kinases 
Erk1 and Erk2 in the Src/Ras/Erk cascade, and many others. All these effects are believed 
to be mediated through membrane-associated or cytosolic ERs and have therefore been 
termed “non-genomic” or “extranuclear” actions of E2. 
 
In what is referred to as transcriptional cross-talk, the “non-genomic” actions of E2 may 
indirectly influence gene expression, by activation of the ER through phosphorylations by 
Src/Erk signalling. To investigate whether environmental estrogens could induce rapid 
extranuclear phosphorylation events, the activation of the Src/Erk pathway in the human 
MCF-7 breast cancer cell line by endogenous and environmental estrogens was 
investigated. By utilising inhibitory agents such as the pure antiestrogen ICI 182,780 and 
the Mek 1 inhibitor PD 98059, the relevance of rapid phosphorylation events along the 
Src/Erk cascade for the expression of selected ER-target genes was analysed. 
 
The organochlorines o,p’-DDT, p,p’-DDE and β-hexachlorocyclohexane (β-HCH) 
showed striking similarities to the effect profile seen with E2. They were able to promote 
    31 
 
 
EDEN Final Report  QLK4-CT2002-00603 
expression of the TFF1 gene, the progesterone receptor (PR) and the cell cycle regulator 
PRAD1 (coding for cyclin D1). In the case of β-HCH, this is surprising, given the 
inability of this chemical to bind the ER.  Gene expression could be inhibited completely 
in the presence of the antiestrogen ICI 182,780, demonstrating that a functional ER is 
necessary to trigger these events. Inhibition of the Erk kinase led to suppressions of gene 
transcription in the case of o,p’-DDT and β-HCH, but not with p,p’-DDE. This suggested 
that o,p’-DDT and β-HCH should be capable of activating the Src/Erk signalling module, 
and that this activation should not occur with p,p’-DDE. Western blot analysis confirmed 
this prediction and showed that o,p’-DDT and β-HCH induced sustained activation of the 
kinases Src and Erk1/2. 
 
These results are of relevance for the testing and screening of estrogenic agents. They 
show that ER-mediated cellular responses are influenced by the characteristics of the 
chemicals that interact with the ER. The screening and testing for estrogen-like activities, 
with its current focus on ER binding and associated events, urgently needs to be 
supplemented by assays that take the wider effect spectrum of xenoestrogens into 
account, especially their non-genomic responses. Otherwise, chemicals such as β-HCH, 
which are unable to bind the ER, but exhibit an otherwise “E2-like” molecular effect 
spectrum, will be missed during conventional screening. 
 
The relevance of xenoestrogen-induced extranuclear signalling in breast cancer 
cells: genomic instability 
Genomic instability is a hallmark of cancer cells and is thought to be the “breeding 
ground” for acquired resistance. The induction of micronuclei, small bodies of (cell) 
nuclear material ejected from the cell nucleus into the cytoplasm of the affected cells, is 
taken as an indicator of genomic instability. E2 is able to raise the frequency of 
micronuclei in ER-competent cells. Studies with MCF-7 cells were undertaken to analyse 
the importance of ER signalling in the induction of these events. A number of estrogenic 
chemicals, including bisphenol A (BPA), certain cosmetics ingredients such as parabens 
and synthetic musks also led to elevated micronucleus frequencies. To investigate 
whether the ability of the ER to promote gene expression is responsible for these effects, 
the influence of antiestrogens such as tamoxifen and ICI 182,780 on micronuclei induced 
by estrogens was investigated. The antiestrogens were without effect. However, inhibition 
of the kinases Erk 1/2 protected against the micronucleus-inducing effects of estrogenic 
chemicals. 
These results suggest that it is the rapid extranuclear signalling events triggered in the 
wake of ER activation that have an influence on micronucleus frequency. Erk 1/2 is 
involved in a cell cycle checkpoint in mitosis. Unwarranted over-stimulation of these 
kinases through ER activation may lead to overriding of this checkpoint with disruption 
of the finely tuned events important in distributing equal chromosome numbers to 
daughter cells and consequent ejection of chromosomes into the cytoplasm where they 
appear as micronuclei. These events may have some relevance in explaining the role of 
estrogens during late stage breast carcinogenesis. 
 
Identification and evaluation of new biomarkers of foetal phthalate exposure 
The Western world is observing certain disorders of male reproductive health such as 
testicular cancer, cryptorchidism, hypospadias and low sperm counts. Though manifesting 
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at different life stages, there is strong evidence that these disorders may have a common 
origin in foetal life. Taken together these disorders have been hypothesised to indicate a 
TDS, which stems from abnormal development and function of SC and/or LC during 
male sexual differentiation (Sharpe & Skakkebæk, 2003). Thus, considerable interest 
exists in identifying the events in the foetal testis that might give rise to TDS. 
 
Foetal exposure of rats to DBP offers a potential animal model in which to explore this 
syndrome (Mahood et al., 2005). The following new endpoints (biomarkers) of DBP 
action on the foetal rat testis have been identified during the EDEN project. These 
biomarkers manifest at different foetal ages and affect one or more of the main cell types 
of the foetal testis. 
 
Delays in germ cell (GC) differentiation 
Foetal germ cell (GC) differentiation is delayed following exposure to high doses of DBP 
(Figure 7) with a ~40% reduction in foetal GC numbers at birth. These DBP effects are of 
particular interest because in human TDS, the carcinoma in situ cells from which 
testicular GC cancers arise in adulthood are themselves thought to arise because of failure 
of normal foetal GC differentiation. However, in DBP-exposed rats a failure of foetal GC 
differentiation has not yet been illustrated, only a transient delay. Postnatally (after 
cessation of DBP exposure), there is also a further delay in GC differentiation with delay 
in their migration to the basal lamina and resumption of proliferation. Consequently there 
is an even bigger deficit in GC numbers (~80% reduction compared with controls) by 
mid-puberty, though this is corrected by adulthood in normally descended (scrotal) testes. 
DBP-exposed animals exhibit a high rate (~75%) of infertility in adulthood, so the 
functional integrity of the adult GC may be compromised as a result of their impaired 
differentiation in foetal life. This will be important to investigate in future studies.  
 
 
Figure 7 Delayed germ cell (arrows) differentiation in foetal testes of DBP-exposed 
animals as illustrated by prolongation of expression of the pluripotency 
factor Oct4 (brown staining). The stage of gestation is indicated at the top of 
each column. 
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Multinucleated gonocytes 
Induction of gonocytes containing not one (as is normal), but several cell nuclei, so-called 
multinucleated gonocytes (MNG) is an indicator of reproductive abnormalities in male 
offspring. Exposure to DBP in utero results in dose-dependent induction of MNG 
throughout the foetal testis that persists postnatally until days 4-6. Studies showed that 
induction of MNG is unrelated to the aforementioned delayed GC differentiation. MNG 
thus occur only during the time window when foetal GC are quiescent and therefore has 
no relationship to proliferation. The mechanisms underlying MNG formation are 
unknown as are its consequences. It appears that MNG induction is a valid indicator of in 
utero phthalate exposure and is one of the most sensitive biomarkers of phthalate action 
as effects are evident at 20 mg/kg/day.  
 
Foetal Leydig cell aggregation 
Exposure to DBP in utero results in dose-dependent induction of LC aggregation in 
central regions of the testis. The number of LC is unaffected, though they are reduced 
notably in size (consistent with their reduced steroidogenic function). The aggregation is 
thought to arise because of migration of LC from more peripheral regions of the testis, but 
the trigger for this is unknown. The most important consequence of DBP-induced LC 
aggregation is that it interferes with the final stages of seminiferous cord formation in 
central regions, resulting in formation of focal dysgenetic areas in which the cords are 
malformed and which contain intratubular LC where the LC are in the wrong place 
(Figure 8). These focal dysgenetic areas persist throughout postnatal life and lack GC in 
adulthood. Similar focal dysgenetic areas are evident in testes of men with testicular GC 
cancer. 
 
 
 
Figure 8 Abnormal location of adult Leydig cells (brown staining) inside of 
seminiferous tubules in the testis of a pubertal rat exposed in utero to DBP. 
Note the reduction in germ cell numbers (pink staining) where the 
intratubular Leydig cells occur. 
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Reduction in Sertoli cell number 
Exposure to DBP in utero results in dose-dependent reduction in SC number at 
embryonal day 21.5 (e21.5), with the highest dose tested (500 mg/kg/day DBP) reducing 
SC number by ~45%. This decrease is probably secondary to the reduction in testosterone 
levels. It remains to be shown whether the DBP-induced reduction in SC number in rats 
persists through to adulthood. However, if this observation were to persist, then it would 
result in reduced capacity to make sperm in adulthood. In the human, this would lead to a 
reduction in sperm counts as is found in TDS.  
 
Phthalates lead to suppression of Leydig cells in foetal testis 
Leydig cells are important in synthesising steroid hormones during various phases of 
development. When pregnant rats were exposed in vivo to various doses of different 
phthalates, major suppression of LC hormone secretion was observed in the foetal testis. 
In males exposed to 500 mg/kg/day DBP administered to their mothers, testosterone 
levels within the testis were suppressed by 70-85% at embryonal day e19.5, when the 
peak of testosterone normally occurs. A similar pattern of suppression of Insl3 protein 
expression in LC is evident. InsL3 is thought to be important in regulating the descent of 
testes into the scrotal sack. Disruption of InsL3 function may be involved in the 
occurrence of undescended testes (cryptorchidism). 
 
The observed hormonal changes are explained by reduced expression of genes involved 
in cholesterol uptake (scavenger receptor B1) and steroidogenesis (P450 side chain 
cleavage enzyme, C17-20 lyase) as well as Insl3. The adverse effects of DBP on LC gene 
expression are first evident in vivo at e17.5. The suppression of LC hormone secretion in 
studies in vivo is clearly important in explaining the high incidence of cryptorchidism and 
the occasional cases of hypospadias as well as the consistent reduction in anogenital 
distance (AGD) in DBP-exposed male offspring. Suppression of testosterone levels 
within the testis may also account for the major reduction in SC number and possibly for 
other changes in the foetal testis. The endpoint disorders related to suppression of foetal 
LC hormone production are directly relevant to human TDS. DBP exposure also causes 
abnormal migration/aggregation of the foetal LC in central regions of the testis. The cause 
is unknown but is presumed to result from altered production/action of cell 
attraction/motility factors. The most important effect of the DBP-induced LC aggregation 
is that it results in the focal formation of malformed seminiferous cords which may 
aberrantly trap foetal LC within them. These ‘focal dysgenetic areas’ containing 
“misplaced” intratubular LC, persist throughout postnatal life and always lack GC (Figure 
8). Similar focal dysgenetic areas have been found in the testes of humans with testicular 
GC cancer. 
 
At a later stage in gestation (embryonal days e19.5-e21.5) another effect of DBP 
treatment on GC becomes evident with the widespread occurrence of multinucleated GC 
(MNG) coupled with the abnormal aggregation of the foetal GC in the centre of the 
seminiferous cords. These effects only first become evident at e19.5 and can be induced 
by e21.5 even if DBP treatment is not started until e19.5. These GC effects are 
completely separate from, and unrelated to, the earlier effect of DBP on foetal GC 
differentiation above. It is likely that formation of MNG and GC aggregation reflect 
abnormal SC function and interaction with the GC. At the same time as MNG form there 
is also a big deficit in SC numbers in DBP-exposed males such that by e21.5, SC numbers 
    35 
 
 
EDEN Final Report  QLK4-CT2002-00603 
are reduced by ~45%. The most likely explanation for this decrease is that it is secondary 
to the reduction in testosterone levels in the testis as a similar reduction in SC numbers is 
observed in androgen receptor knockout mice.  
 
Phthalate induced suppression of Insl3 and testicular descent 
Following the identification of Insl3 as the key hormone regulating the first phase (trans-
abdominal migration) of testis descent, EDEN has developed antibodies for measuring 
this protein. Insl3 immunoexpression in foetal LC is highly expressed in control males at 
e17.5 and e19.5 (during the period of trans-abdominal testis descent) and is notably lower 
at e21.5. In animals exposed in utero to 500 mg/kg DBP from e13.5, Insl3 
immunoexpression was suppressed in most animals at e17.5-e19.5 but was not different 
from controls at e21.5. However, when Insl3 expression in LC was compared in normally 
descended and abnormally descended testes in DBP-exposed animals, there was no 
consistent relationship between the level of Insl3 immunoexpression and testis position. It 
was therefore concluded that there was no straightforward relationship between DBP-
induced suppression of Insl3 in LC in the foetal testis and the normality or otherwise of 
testicular descent. Instead, failure of normal testis descent, as occurs with high frequency 
in animals exposed in utero to high doses of DBP, may be the consequence of combined 
suppression of Insl3 and testosterone production. Alternatively, it may be that Insl3 
immunoexpression detected using the antibody generated may not accurately reflect 
changes in secretion (and thus the blood levels) of Insl3. The latter possibility is 
supported by the finding that neither in utero exposure to flutamide nor to DES resulted 
in consistent reduction in Insl3 immunoexpression in LC at e19.5, whereas similar 
treatment with flutamide did result in a significant reduction in Insl3 gene expression and 
a similar, and larger reduction in mRNA expression, has been reported by others after in 
utero exposure of mice to DES in which cryptorchidism was also induced.  
 
InsL3 receptor expression in the gubernaculum 
Various tissues were collected from rats at ages spanning from foetal life through to 
adulthood with a particular focus on the reproductive tract (testis, efferent ducts, 
epididymis, gubernaculum). Thus enabling an evaluation of the distribution and level of 
expression of receptors for Insl3 (the LGR8 receptor) using RT-PCR and 
immunohistochemistry. As it was previously shown that Insl3 protein expression was 
detectable in the gubernaculum, RT-PCR was utilised to detect whether Insl3 mRNA 
expression could also be shown. More limited evaluation of LGR8 immunoexpression in 
the testis and reproductive tract (including the gubernaculum) was also undertaken. It was 
shown that mRNA for LGR8 was expressed heavily in the gubernaculum throughout 
foetal and postnatal life, a finding confirmed at the protein level in more than one 
laboratory. 
 
These findings confirm that the gubernaculum is a key target for Insl3 in foetal life when 
testis decent is occurring. It was also shown that no mRNA for Insl3 can be detected in 
the gubernaculum of the rat, despite localisation of the protein by immunohistochemistry. 
It was concluded that the Insl3 protein detected in the gubernaculum was protein bound to 
its LGR8 receptor. Another key finding was that LGR8 mRNA and protein expression is 
not confined to the gubernaculum but is evident in other reproductive tract tissues, 
notably in the efferent ducts and epididymis during foetal and postnatal development. 
This implies that Insl3 from the foetal LC may play a wider role in development of the 
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male reproductive tract, a process previously considered to be largely androgen-regulated 
(the androgens also emanating from the foetal LC). Unexpectedly, it was found that 
LGR8 protein is expressed in foetal GCs, implying a potential (but unknown) role for 
Insl3 in the development of these cells. Some of the abnormalities in developing foetal 
GCs found in rats exposed in utero to DBP, which coincide with suppression of Insl3, 
could be attributable to altered action of Insl3. It is concluded that, in the rat, the 
gubernaculum is an important target for the actions of Insl3 during the period when the 
testis descends through the abdominal cavity consistent with a role for Insl3 in testis 
descent. However, judged on the wider expression of Insl3 receptors throughout the foetal 
reproductive tract and in foetal GCs in the testis, it seems likely that there are other, 
unknown functions of Insl3 in development of the male reproductive system.  
 
Relationship of Insl3 expression to size, number and androgen production by foetal 
Leydig cells in rats exposed to treatments in utero 
These studies involved treatment of time mated pregnant rats with daily doses of DBP 
varying from 4 to 500 mg/kg/day or with vehicle (= controls) with the treatment period 
ranging from e13.5 to e21.5. Exposed male offspring have then been sampled at foetal 
ages ranging from e15.5-e21.5 and LC immunoexpression of Insl3 evaluated and 
compared with LC size (= cytoplasmic volume) and the expression of factors involved in 
different steps of steroidogenesis (SR-B1, P450ssc) or with other roles in LC (Inhibin-a, 
CRABP-II); at certain ages (e19.5, e21.5) intratestcular levels of testosterone have also 
been measured. Most attention has been focused on males exposed in utero to 500 
mg/kg/day DBP because this is the only dose level that causes a high incidence (>70%) of 
(mainly unilateral) cryptorchidism and is the only dose to consistently reduce 
immunoexpression of Insl3 at certain foetal ages. 
 
In addition, we have undertaken similar evaluations in foetal males from pregnant dams 
that have been treated with either 100 mg/kg/day flutamide from e15.5 until e21.5. These 
studies have shown that Insl3 immunoexpression in foetal LC appears to change more or 
less hand in hand with steroidogenic capacity and with the expression of steroidogenic 
enzymes that are highly regulated, such as P450ssc. Thus, in controls as testosterone 
levels and P450ssc immunoexpression increase from e15.5 to a peak at e19.5, so does the 
intensity of immunoexpression of Insl3. Furthermore, exposure to 500 mg/kg/day DBP 
results in a similar decrease in immunoexpression of Insl3 as in P450ssc, a change that 
also correlates with reduction in LC size. 
 
In contrast, exposure in utero to flutamide does not affect immunoexpression of either 
Insl3 or P450ssc. However, it remains uncertain whether immunoexpression of Insl3 
provides an accurate reflection of the level of secreted hormone, although for P450ssc 
there is clear evidence that reductions in immunoexpression (such as after treatment with 
DBP) correlate closely with reduction in testosterone production. With such fundamental 
reservations, and in the absence of data to correlate LC immunoexpression of Insl3 with 
levels of secreted Insl3, it was decided that further detailed evaluation of LC Insl3 
immunoexpression in relation to other factors, would be pointless.  
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Association of InsL3 blood levels with reproductive disorders in humans and rats 
Human studies 
To characterise the relationship between serum Insl3 levels and male reproductive 
function, serum Insl3 levels were measured in blood samples collected from cryptorchid 
boys and from boys with normally descended testes. Insl3 levels were also measured in a 
large number of blood samples from male and female children of various ages from the 
neonatal period through puberty to adulthood. Additionally, blood samples from adult 
men during and after treatment-induced gonadotrophin suppression (which will suppress 
LC function) were evaluated for Insl3 levels. 
 
The studies showed that serum InsL3 in normal men is not acutely sensitive to exogenous 
FSH or LH/hCG, but nevertheless is dependent on the stimulatory activity of 
gonadotrophins on LC. Suppression of endogenous gonadotrophins results in a marked 
decline in serum InsL3, and subsequently InsL3 is acutely sensitive to LH action. 
Subsequent to long-term gonadotrophin suppression, InsL3 does not recover to the same 
degree as does testosterone, suggesting that InsL3 may be more sensitive than 
testosterone to impaired LC function in adulthood. Reduced blood levels of InsL3 in 
cryptorchid boys suggests impairment of LC function in cryptorchid testes and supports 
the hypothesis that cryptorchidism is associated with a primary testicular disorder; 
however, the magnitude of difference between blood Insl3 levels in normal and 
cryptorchid boys when measured postnatally is modest (levels overlap for the two 
groups). This may imply that Insl3 alone is not the most critical determinant of testis 
descent. 
 
Alternatively, it is possible that measurement of Insl3 levels postnatally does not 
accurately reflect levels in foetal life when Insl3 action on the gubernaculum plays its role 
in testis descent. Measurement of Insl3 levels in amniotic fluid and relating levels found 
to subsequent normality or not of testis descent may resolve this issue. 
 
Rat studies 
To characterise the relationship between Insl3 mRNA or protein expression levels in 
foetal life and testicular descent and non-descent (cryptorchidism), Insl3 expression in 
foetal testes and in the LC of such testes has been evaluated in rats exposed in utero to 
DBP, flutamide or to other EDCs (TCDD, p’p’-DDE). Immunoexpression of Insl3 in the 
adult generation of LC has also been evaluated in normal rats during progression through 
puberty into adulthood or after various treatments likely to affect LC function; blood 
samples from some of the latter treatment groups have been evaluated for Insl3 levels 
during development and validation of the rat Insl3 assay.  
 
Finally, a transactivation assay for Insl3, which might serve to screen chemicals for Insl3-
gene modifying activity was developed and tested. Results for blood levels of Insl3 in the 
rat have been very limited and the rat Insl3 assay has still not completed validation and 
optimisation. However, the results obtained are largely in tune with the findings from the 
human in showing that factors that suppress gonadotrophin secretion and/or LC 
development postnatally suppress Insl3 levels. In the foetus, it has been shown that a 
maternal treatment (DBP) that induces a high incidence of cryptorchidism in the male 
offspring (due primarily to impaired development of the gubernaculum), results in major 
suppression of Insl3 gene and protein expression. However, no consistent relationship 
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was found between cryptorchidism and the level of Insl3 expression, perhaps suggesting 
that the parallel suppression of testosterone production by DBP may also be an important 
factor in determining failure of testis descent. 
 
Various pieces of evidence suggest that testosterone, or other androgens, might play a 
role in stimulating Insl3 expression, though this needs further investigation. The Insl3 
reporter gene (transactivation) assay shows that there are no direct effects of estrogens in 
this system whereas androgens may be weakly stimulatory. The human and rat studies 
support a role for Insl3 in testis descent, but have also shown that there does not appear to 
be a simple, straightforward relationship between the normality of testis descent and Insl3 
expression in the testis or when measured (postnatally) in blood. However, this 
conclusion is based on limited material. Postnatally, and particularly in adulthood, Insl3 
levels may provide important information on the normality or not of LC function and 
more detailed comparison of testosterone and Insl3 levels should establish the relative 
utility and usefulness of these two markers. Transactivation assays for Insl3 probably 
have limited utility.  
 
In vitro cell screening system for chemicals effecting InsL3 gene expression 
Mouse tumour LC (mLTC-1) were transfected with a reporter construct containing the 
Insl3 promoter in front of the luciferase reporter gene. This promoter possesses three SF-1 
binding sites which have been shown to be important for regulation of the mouse Insl3 
gene. Transfected cells were used to screen for the effects of E2, testosterone and hCG on 
Insl3 gene expression in vitro. The Insl3 reporter gene assay showed that there were no 
direct effects by estrogens, whereas androgens slightly stimulated gene activity. It is 
therefore concluded that this Insl3 reporter gene assay cannot be used to screen 
effectively for chemicals likely to have an impact on Insl3 gene expression. 
 
ELISA for the measurement of InsL3 in human and rat blood/testis extracts 
An ELISA for the measurement of InsL3 in tissue extracts was developed. Extracts from 
female rats and from castrated and EDS-treated male rats (EDS destroys the Insl3-
producing LC in the testes) did not produce signals, as expected. In male rats, there was 
an increase in Insl3 levels at around puberty, reaching a peak at day 43 and then declining 
somewhat in adulthood, a pattern that parallels that found for testosterone in numerous 
earlier studies. It can be assumed that Insl3 must have a function in the adult rat in the 
postpubertal age. Also, male rats appeared to have roughly ten times more Insl3 in their 
blood than male humans. Drastically reduced were Insl3 levels in blood of adult male rats 
which were exposed to DBP in utero, regardless of their actual testicular status. This has 
to be investigated in further detail and points towards an obstruction of LC or general 
testis function by DBP already in the foetal stage and lasting past puberty, also in rats in 
which the testes descend normally into the scrotum.  
 
Hypothalamic-pituitary sensitivity to endocrine disruption 
The HP unit plays a central role in the regulation of reproductive function. During early 
stages of development, the HP unit is highly sensitive to the organising effects of 
endogenous sex steroids. This raises the possibility that the developing HP unit might also 
be a potential target for the actions of EDCs. The aim was to explore the mechanisms, 
consequences and new endpoints of endocrine disruption at the HP unit, whose sensitivity 
to the organising effects of sex steroids (endogenous and synthetic) is expected to be 
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higher than that of the peripheral sex organs (internal and external genitalia). Most 
attention has focused on the characterisation of the deleterious effects of EDCs on 
reproductive health and analysis of direct effects at peripheral sex organs. Conversely, 
little was known about their potential actions on central reproductive systems. However, 
some of the putative ‘clinical correlates’ of endocrine disruption of reproductive function 
(e.g., disturbed timing of puberty and some forms of infertility) might theoretically stem 
from alterations at the HP unit. 
 
Results have furthered knowledge on the physiological mechanisms controlling 
reproductive function at the HP unit and have set the basis for the identification of novel 
molecular mechanisms, end points and biomarkers for exposure/ action of EDCs at this 
site. Overall, the studies reinforced the notion that the developing HP unit is sensitive to 
the effects of synthetic estrogens, as monitored by molecular biomarkers, such as changes 
in expression of progesterone receptor (PR) and KiSS-1 genes at the hypothalamus and 
globin genes at the pituitary. Interestingly, some of these changes were tightly related to 
concomitant alterations in basal serum levels of luteinising hormone (LH) which is a 
putative marker for disruption of function of the gonadotropic axis and were also detected 
after neonatal exposure to the aromatisable androgen, testosterone propionate, the 
antiandrogen, flutamide, and BPA. The analyses so far conducted from in vivo mixture 
experiments, testing the effects of exposures to selected antiandrogenic EDCs alone or in 
mixtures, have failed to identify consistent changes in hypothalamic or pituitary 
expression of some of the above gene markers at early periods of postnatal development 
(postnatal day - PND 16). However, further analyses at later age points are required in 
order to define the potential impact at the HP unit of such exposures in terms of activation 
of gonadotropic axis at puberty and its function later in life. 
 
Mechanistically, findings on the hypothalamic KiSS-1/GPR54 system have helped to 
define not only the fundamental role of KiSS-1 as a pivotal element in the central 
regulation of the gonadotropic axis in normal conditions but also its possible function as a 
target for endocrine disruption of reproductive function by exposure to estrogenic (and 
possibly androgenic) EDCs during critical periods of sexual differentiation of the HP unit 
(Figure 9). Also relevant from a mechanistic stand point, are results illustrating that 
selected EDCs, including DDT isomers can stimulate the GnRH secretion in vitro in the 
immature female hypothalamus through both rapid and/or slow effects and they involve 
both estrogen and dioxin receptor pathways. These effects can account for the precocious 
sexual development observed in female rats after early exposure to E2 or DDT in vivo, 
and might provide (at least partially) the molecular basis for the observation of precocious 
puberty in girls from underdeveloped countries migrating to Europe and USA for 
adoption. Thus, results have enlarged the basic knowledge on the consequences and 
potential modes of action EDCs (with estrogenic, androgenic or antiandrogenic activity) 
at different levels of the reproductive (or HP-gonadal) axis in mammals, which are likely 
to involve direct effects at the HP unit. 
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Figure 9 Pivotal role of KiSS-1 neurons in the hypothalamic circuitries controlling 
GnRH neurons and, thereby, reproductive function. Studies of neonatal 
exposure to synthetic estrogen and androgen point out that (i) functional 
organisation of neuronal circuits involving KiSS-1 neurons (so-called KiSS-
1 system) is sensitive to the organising effects of sex-steroid acting 
compounds during critical periods of sexual differentiation of the brain; and 
(ii) reproductive defects linked to inappropriate exposures can be 
ameliorated by exogenous administration of kisspeptins. Altogether, these 
observations are the first to suggest that the hypothalamic KiSS-1 system 
might be a target for endocrine disruption of reproductive function at the HP 
unit. 
 
Dose-response analyses showed that neonatal exposure to doses as low as 1-10 mg E2 
benzoate per rat were able to induce significant changes in the relative mRNA levels of 
KiSS-1 (decrease) and PR (increase) at the hypothalamus, as well as in the expression 
levels (increase) of alpha- and beta-globin genes at the pituitary. The fact that these 
changes were tightly related to concomitant changes (decrease) in basal serum levels of 
LH, i.e. a conventional marker for disruption of function of the gonadotropic axis, 
strongly suggests that these might be regarded as genuine markers for potential endocrine 
disrupting events at the HP. Moreover, some of the above markers were also altered in 
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expression after neonatal exposure to the aromatisable androgen, testosterone propionate, 
the antiandrogen, flutamide, and/or the putative xenoestrogen, BPA, which reinforces the 
contention that expression of those genes (PR, KiSS-1, globins) at the HP unit might 
serve as reliable, highly sensitive, continuous biomarkers of exposure (and eventual 
disruption at this level) to sex steroid-like compounds during critical periods of sexual 
differentiation. From a mechanistic perspective, some of the identified changes in gene 
expression in the experimental models of exposure to synthetic estrogenic and related 
compounds might not only be relevant in terms of setting thresholds and sensitivity for 
endocrine disruption at the HP unit, but they may provide also novel information 
regarding end points and mechanisms for endocrine disruption at this level of the 
reproductive axis. The most salient example of this contribution is the definition of the 
hypothalamic KiSS-1 system not only as a pivotal element in the central regulation of the 
gonadotropic axis in normal conditions, but also as a putative target for endocrine 
disruption by exposure to estrogenic (and possibly androgenic) compounds during critical 
periods of sexual differentiation of the HP unit. Likewise, altered expression of PR at the 
hypothalamus, and eventually of globin genes at the pituitary, may prove mechanistically 
relevant to explain some of the alterations in development and/or function of the 
reproductive axis following early exposure to sex steroid-like acting compounds. 
 
Rat studies were subsequently conducted to characterise the effects and threshold doses 
(sensitivity) of EDCs such as DDT, in terms of induction of precocious activation of the 
HP unit, using the rat hypothalamic explant incubation paradigm to investigate for novel 
molecular mechanisms for such a precocious activation. In addition, specific studies to 
define animal models for the in vivo characterisation of the above phenomenon were 
conducted. By a combination of in vitro and in vivo analyses, results show that some 
EDCs, including DDT isomers, are able to stimulate the GnRH secretion in vitro in the 
immature female hypothalamus through both rapid and/or slow effects and they involve 
both estrogen and dioxin receptor pathways. These effects can account for the precocious 
sexual development observed after early exposure to E2 or DDT in vivo, thus providing 
the molecular basis for the clinical observation of precocious puberty in foreign girls 
migrating for adoption in several European countries.  
 
Development of new techniques and novel endpoints 
A suite of advanced tools for diagnosing and assessing endocrine disruption in fish and 
mammals has been successfully developed. These tools include: 
  
• Antibodies and real-time RT PCR protocols for quantifying EDC-inducible 
molecular responses. 
• Customised microarrays to screen EDC-responsive genes in zebrafish. 
• Sensitive screening assay for estrogenic EDCs using an aromatase reporter 
system. 
 
Utilisation of these tools have led to the evaluation of the mechanisms by which EDCs  
interfere with sex steroid synthesis and disturb sexual development and reproduction of 
fish, and identifying novel targets of ED action beyond the reproductive axis.  
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Mechanisms of expression regulation and functional roles of aromatase cyp19 in 
zebrafish 
Aromatase is a key enzyme of steroidogenesis important in the regulation of endogenous 
levels of estrogens/androgens and thus directly influencing sexual differentiation and 
reproduction of vertebrates. Zebrafish have two aromatase forms which are expressed in 
the gonads (cyp19a1) and in the brain (cyp19a2). The brain form of aromatase is 
responsive to estrogens due to the presence of functional ERE in the promoter (Menuet et 
al., 2005). Prediction of dioxin-responsive elements (DREs) in the promoters of both 
cyp19a1 and cyp19a2 had suggested the direct regulation of these genes by aryl 
hydrocarbon receptor (AhR) and thus susceptibility to the dioxin exposure; however, in 
vitro study of these promoters with use of site-directed mutagenesis showed that these 
sites are probably not functional. Further reinforced by electrophoretic mobility shift 
assays and in vivo exposures of zebrafish larvae, the data proved that the cyp19 
aromatases in zebrafish are not directly regulated by AhR via DREs. Interestingly, the 
study revealed an important mode of crosstalk between ER and AhR, showing that 
dioxins are able to regulate the expression of the genes containing a functional ERE, not 
involving DREs on the promoter. These actions of dioxins may be either estrogenic 
(leading to stimulation of estrogen-receptor element-mediated transcription) or 
antiestrogenic (leading to attenuation of normal E2-induced upregulation of 
transcription), depending on the absence or presence of the estrogen receptor ligand, 
respectively. Thus, at the different stages of development, or in the different target 
organs, which might differ in estrogen content, the actions of dioxins may also be 
different. Similarly, the actions of dioxins in the environment can also be quite different 
depending on the presence or absence of estrogenic substances in the same exposure 
solution. 
 
The specific sites of aromatase cyp19a2 expression in the brain were identified, giving a 
hint towards the possible function of this enzyme in the brain. Presence and activities of 
the aromatases get disturbed (in time and total activity) in the presence of xenoestrogens. 
The previously assumed role of the brain aromatase in the sexual development could not 
be confirmed, pointing to the fact that sexual development in zebrafish is probably a 
multifactorial process.  
 
Aromatase can also affect functions outside the reproductive system such as 
neurogenesis. Figure 10 illustrates the consequences of aromatase disruption in early life 
stages of zebrafish resulting in a statistically significant reduction of neuromast number.  
 
          
 
Figure 10 Embryos were injected with morpholinos to suppress zfcyp19a and zfcyp19b 
expression during early development. Left: control zebrafish larva, with 
neuromasts along the head and the lateral line (yellow dots). Right: 
morpholino-injected zebrafish with reduced number of neuromasts. 
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Developing and utilising transgenic zebrafish for detecting effects of EDCs 
Candidate genes identified for the construction of transgenic zebrafish 
From the gene expression experiments carried out using DNA-microarray techniques and 
RT-PCR, the ERE is recommended for constructing transgenic zebrafish. To enhance the 
signal, the use of a reporter gene under the control of 3 to 4 EREs is considered best 
practice. In addition, the regulation of aromatase by EDC renders aromatase an interesting 
target gene for the detection of EDC effects, as the expression of brain aromatase gene is 
significantly stimulated by estrogen. The promoter region of this gene (also containing an 
ERE) could therefore also be a good candidate for transgenic zebrafish. 
 
Transgenic zebrafish model 
Significant progress towards developing lines of useful transgenic fish has been made and 
efforts are continuing post EDEN. Injection of the gene construct into embryos at the one 
cell stage is shown in Figure 11.  
 
Injection of the conventional vector consisting of zfcyp19b and the enhanced green 
fluorescent protein (EGFP) coding sequence into zebrafish embryos did not result in 
sufficiently high expression levels. This was irrespective of the different injection 
methods utilised and exposure to E2, which is known to activate zfcyp19b promoter in 
zebrafish embryos (Menuet et al., 2005). The use of the previously recommended 
(Koester and Fraser, 2001) amplification system based on transcriptional activator 
Gal4VP16 increased the signal, but also introduced the problem of unspecificity, as the 
EGFP expression was frequently observed in the unexpected sites outside the brain. 
However, EGFP expression in the brain was observed most often and faded slower in the 
course of development than in other sites. Further, brain expression of EGFP, in contrast 
to expression in other tissues, was stabilised by exposure to estrogen and destabilised by 
exposure to ER antagonist, indicating its possible zfcyp19b-specificity. This work, 
although due to technical problems not leading to the production of transgenic zebrafish 
line suitable for EDC detection, had nonetheless provided the evaluation of different 
methods available for producing zebrafish expressing EGFP under the control of natural 
and artificial promoters.  
 
For transgenic zebrafish possessing an estrogen-responsive promoter (an ERE) connected 
to the GFP gene, the current status is one close to establishing one or more lines. 
However, one further round of screening of the F1 fish is required, followed by breeding 
a further generation (F2 fish), which will need to be screened for the presence of the 
transgene. Unequivocal evidence of the presence of the transgene in some (probably 50%) 
of the F2 fish would indicate germline transmission of the transgene, and allow a 
transgenic line to be established.  
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Figure 11 Injection of the 2 x ERE-EGFP vector into a zebrafish embryo at the one-
cell stage. 
 
Three factors have been identified as playing key roles in the production of transgenic 
fish, these being the number of eggs injected, the time involved in raising and screening 
offspring and luck! The more eggs that are injected with the transgene, the greater the 
chance of producing a useful transgenic line of fish. A great deal of time, and costs, are 
associated with rearing fish to adulthood, when they can reproduce, and produce the next 
generation. After a batch of eggs has been injected, it takes 4 to 6 months for the fish to 
reach sexual maturity. Only by screening the next generation can it be ascertained 
whether or not the transgene has been transmitted to the next generation. Even if it has, it 
will be to only a small proportion of the offspring, and these need to be identified, then 
reared to adulthood so that they in turn can reproduce. A minimum of 3 generations, and 
hence about 18 months, are required to unequivocally establish whether or not a transgene 
has been stably integrated into the germline. Efforts to study these fish will continue, in 
the hope that a useful line of transgenic fish can be obtained.  
 
Utilising transgenic ZER-CALUX® zebrafish, an exposure study to the potent estrogen 
EE2 was carried out to determine the usefulness of transgenic reporter fish in detecting 
endocrine activities of chemicals and polluted environments. As expected, the fish 
synthesised VTG in response to EE2. Similar results would have been obtained if normal 
(not transgenic) fish had been used. All 3 concentrations of EE2 (up to 10 ng/L) produced 
significant responses, albeit only at the highest concentration was the response very 
pronounced. Also, as expected, luciferase was induced in the liver (the transgenic fish 
produce luciferase in response to exposure to estrogen). Given that VTG was synthesised 
in the liver in response to the EE2, it would have been extremely surprising if luciferase 
had not been induced in that organ. Luciferase induction was also investigated in the 
brain and testes. The results demonstrate that in the brain there was no luciferase 
induction above the control level in the fish exposed to EE2. This might imply that the 
brain is unresponsive to EE2, or responsive but less sensitive than the liver. Another 
explanation is that the EE2 could not reach the brain, possibly due to the existence of the 
blood:brain barrier. In complete contrast, exposure to the highest concentration of EE2 
caused a major induction of luciferase in the testes (Figure 12). This can mean only that 
functional ERs exist in the testes. This tissue therefore becomes a prime candidate for 
effects caused by environmental estrogens. A more complete investigation of many 
different tissues may demonstrate that other tissues/organs are also estrogen-responsive.  
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Figure 12 Luciferase induction in the brain (A) and testes (B) of transgenic zebrafish 
exposed to the potent estrogen ethinylestradiol (EE2). 
 
Development of an in vivo model for the screening of antiandrogenic effects in fish 
Until recently, there was no in vivo assay for the screening of antiandrogens available, 
apart from the Hershberger assay. An opportunity offered itself to develop an alternative 
to the Hershberger assay by exploiting a fish model based on the three-spined stickleback. 
Male stickleback synthesise large quantities of the glue protein spiggin during nesting. 
Spiggin induction is under the control of androgens. It is quite variable in male fish where 
it is influenced by light, social hierarchies and reproductive status. 
 
Female sticklebacks exposed to androgens also induce the protein, but the response is 
much more uniform. Antiandrogenic activities of test chemicals can be detected as a 
downturn in kidney spiggin levels in female fish co-exposed to a stable androgen 
(dihydrotestosterone). A standard operating procedure for this assay was developed as 
part of EDEN Theme 2 work (Katsiadaki et al., 2006). The protocol was applied to the 
low-dose and mixture studies in Theme 4. 
 
*
B Testes 
A Brain 
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Discussion 
Considerable progress has been made in uncovering the mechanisms underlying EDC 
action at various different levels of biological organisation. The importance of signalling 
cross-talk in the effects of xenoestrogens on gene expression was highlighted. Foetal 
exposure to certain phthalates leads to a multitude of effects, with delays in GC 
differentiation, major disruption in cell migration during development and reductions in 
SC numbers being prominent features of DBP action.  
 
The role of InsL3 in relation to testes descent and androgen production by foetal LC has 
been clarified and has revealed complex interrelations not previously anticipated. 
 
The sensitivity of the HP unit to environmental and endogenous estrogens has been 
characterised and possible implications in relation to precocious puberty assessed. 
 
Substantial progress has been made towards the study of endocrine disruption in fish with 
activities including the development of microarrays for assessing endocrine disruption in 
zebrafish, establishing sensitive screening tools for endocrine disruption in fish, 
evaluating the mechanisms by which EDCs interfere with sex steroid synthesis and 
disturb sexual development and reproduction of fish, and identifying novel targets of 
EDC action beyond the reproductive axis. 
 
Candidate genes for developing transgenic zebrafish for the detection of EDC effects 
have been identified, but the technical difficulties in producing transgenic fish proved to 
be significant.  
 
Conclusions 
The work produced in Theme 2 of EDEN allows the following conclusions: 
 
• The screening for EDC, which is mainly based on measuring interactions with 
steroid receptors, has experienced substantial advancement through the EDEN 
project by pointing to the importance of aromatase/steroid synthesis and of signal 
transduction events in endocrine disruption. To avoid the risk of overlooking 
endocrine active chemicals, existing screening tools should be expanded to take 
account these alternatives modes of action. 
 
• Certain phthalates are able to induce effects in an experimental rat model that are 
of direct relevance to understanding the TDS in man. DBP essentially delays 
differentiation of GCs, interferes with the finely tuned events that govern the 
migration of various cell types during development, thereby leading to misplaced 
cells and aggregation of LC. It also reduces the number of SC in the developing 
testis, thereby limiting the number of GCs a testis can support. 
 
• InsL3 secreted by foetal LC may play a wider role in the development of the male 
reproductive tract than thought previously. This process was thought to be largely 
controlled by androgens. There was no clear relationship between DBP-induced 
suppression of InsL3 in foetal LC and the normality or otherwise of testicular 
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descent. LC InsL3 immunoexpression did not provide accurate reflections of the 
levels of secreted InsL3. 
 
• The development and validation of an assay for the measurement of InsL3 blood 
levels was successful, but the differences in blood InsL3 levels in normal and 
cryptorchid boys were too small to exploit InsL3 as a biomarker indicative of 
disruption of testis descent. It appears that InsL3 alone is not the most critical 
determinant of testis descent. 
 
• The HP unit proved to be exquisitely sensitive to the effects of several EDC, and 
the effects may account for precocious sexual development observed after early 
EDC exposure. 
 
• The development of a transgenic fish model for the detection of EDC effects 
proved to be technically too demanding to be completed in time, but efforts 
continue to complete this project after conclusion of EDEN. 
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THEME 3 - INDICATORS OF IMPAIRED MALE 
REPRODUCTIVE FUNCTION 
 
Overview and Objectives 
One of the first observations suggesting deteriorating male reproductive health was an 
apparent decline in sperm numbers of normal men reported 15 years ago (Carlsen et al., 
1992). After that meta-analysis it became obvious that prospective and international 
multicentre studies are needed to assess temporal and regional differences in semen 
quality. Driven by the increased concern about deteriorating male reproductive health in 
several industrialised countries, a number of studies on reproductive health in men from 
the general population have been carried out in different European countries during the 
last 5-7 years. These studies have shown that large regional differences in male 
reproductive health exist within Europe. It was especially noted that Finland was clearly 
contrasting Denmark with a better semen quality. The recent findings of poor semen 
quality among at least 20 % of normal young men in Denmark raise the question whether 
it has reached a level where it may influence on pregnancy rates in the population.    
 
The European studies on male reproductive health have provided a large data set that has 
been entered into a central research database in Copenhagen. This database contains data 
on clinical findings, semen quality, hormone levels, lifestyle factors, and exposures, 
which can be explored to search for causal factors. However, the previously conducted 
European studies on male reproductive health did not include data from Germany. The 
German population has experienced very different industrial history between East and 
West after the Second World War and although originating from the same genetic pool 
the young men of the former East and West Germany may have been exposed very 
different environment during their foetal development and childhood. Thus comparison of 
young men born in East and West Germany may provide additional clues to factors 
affecting male reproductive health. 
 
It has been hypothesised that the observed adverse changes and regional differences in 
male reproductive health are attributable, at least partly, to altered/different exposures to 
endocrine disrupting agents during foetal development, leading to manifestation of the so 
called TDS. The focus has mainly been on SC function as disturbed SC function is 
suggested to cause the reduction in semen quality and development of testicular cancer. 
Less attention has been given to the possible adverse effects on LC function, although 
disturbed LC function has distinct effects on male reproductive health - mainly through 
altered testosterone production. Testosterone plays a key role in the development of the 
external male genitalia and in the adult man it drives spermatogenesis and libido. Based 
on longitudinal studies there is general agreement that male serum testosterone levels 
decline with age indicating a decrease in LC function with increasing age. However, 
cross-sectional surveys have demonstrated very different rates of decline, some even 
showing no decrease in testosterone levels with increasing age. The hypothesis is that this 
discrepancy in the age related decline in serum testosterone between cross-sectional and 
longitudinal studies might be due to confounders such as secular or cohort effects on 
hormone levels, which may hide or blunt the effect of aging.  
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The objectives of theme 3 are to: 
 
• Expand the central database on male reproductive health to include also data on 
male reproductive health in the former East and West Germany and explore 
possible differences. 
• Expand this database with new data on andrological parameters of currently 18-20 
year old men in different European countries in order to follow secular trends in 
male reproductive health. 
• Exploit data in the central database to identify environmental and lifestyle factors 
associated with affected male reproduction. 
• Use unique Danish registers on births and abortions to evaluate a possible effect 
of the poor male fecundity on pregnancy rates among their presumed partners – 
the younger cohorts of women.  
• Test the hypothesis that the discrepancy in the age related decline in serum 
testosterone between cross-sectional and longitudinal studies might be due to a 
population-level decline in male serum testosterone over the last decades. 
 
Materials and Methods 
Semen quality studies and hormone analyses 
For expanding the data on male reproductive health in relation to exposure and lifestyle, a 
number of 1004 men at the age of 18-20 from the former West (Hamburg, 504 men) and 
East (Leipzig, 500 men) Germany were chosen from the compulsory medical examination 
for military eligibility. If both men and their mothers were born in the area where the men 
were currently residing, they were included in the final analysis (Hamburg, 334 men and 
Leipzig, 457 men). All participants were instructed to abstain from ejaculation for at least 
48 hours prior to clinic attendance whereupon a physical exam and blood and semen 
samples were obtained. Prior to attendance, a questionnaire was completed including 
information on age and previous or current diseases, including any known history of 
fertility. From Finland, 18-20 year old men (n=150) were studied after invitation by letter 
as a reiteration of a study performed 3 years ago. Also the military conscripts born in 
1982 and 1983 were invited to participate in the follow up study. 185 men (born 1982) 
were first examined in 2001 and 116 men re-examined in 2003. 195 men (born 1983) 
were first examined in 2002-2003 and the second round of re-examinations was 
completed 2004-2005. Participation rate in the second examinations was 57%. For the 5 
year follow up, 100 men (born 1979-1981) and 51 men for the 2-year follow up (born 
1983) of previously recruited cohorts were re-examined. By including some of men 
previously analysed (born between 1979-1981 and in 1983), secular changes in Finnish 
male reproductive health could be evaluated. 
 
Clinical examination and semen analysis were standardised according to a rigid protocol 
established in previous European studies on male reproductive health. Laboratories 
participated in an international quality control program and morphological analysis of 
semen samples and hormone levels were analysed in centralised laboratories (Jørgensen 
et al., 1997; Menkveld et al., 1990). Serum levels of follicle stimulation hormone (FSH), 
LH and sex hormone-binding globulin (SHBG) were determined using a time-resolved 
immunofluorometric assay. Testosterone and E2 levels were determined using time-
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resolved flouroimmunoassay and inhibin-B by a specific two-sided enzyme 
immunometric assay.  
 
Correction for confounding factors 
Numerous confounding factors (e.g. age, year of birth, duration of abstinence) affecting 
semen and hormone parameters, the effect of duration from ejaculation to assessment of 
motility for motility parameters and hour of blood sampling for effect on sex hormone 
levels were all tested in a multiple linear regressions analysis, taking possible interactions 
into account. To correct for the skewed distribution, semen volume, sperm concentration, 
total sperm counts and the hormone results were natural logarithmic transformed before 
analysis. Motility was logit-transformed before analysis. The quality control results were 
used to adjust sperm concentration and total sperm count to achieve results comparable 
with those previously reported from the Nordic-Baltic area. Data evaluation between 
group differences in self-reported previous diseases were statistically analysed by a 
Pearson Chi-Square test, and differences in age, years of school attendance, height, 
weight, BMI and testis sizes were tested by Mann-Whitneys tests. Data was entered into 
an existing SPSS database on male reproductive health, which was restructured to 
facilitate incorporation of exposure data. 
 
Studies of conception rates 
In order to evaluate trends in the number of pregnancies obtained without assisted 
reproduction (ART) rather than the number of births, the “total natural conception rate” 
(TNCR) was studied, defined here as:  
 
Total natural conception rate = total fertility rate + total induced abortion rate – ART conception rate 
 
where ART represents assisted reproductive techniques, which included IVF and ICSI 
(and excluded intrauterine inseminations due to incomplete data). 
 
In Denmark, all citizens are registered with a unique personal identification number 
(CPR-number) from the Danish Civil Registration System. In order to estimate the TNCR 
we used the following five registers and data sources: The Medical Danish Birth Registry, 
The Registry of Legally Induced Abortions, National Patient Registry, The Danish IVF 
Registry and Statistics Denmark. For each entry in each of these registries, the CPR-
number is recorded which allows an identification of all registered persons and thus also 
linking of data from different registries. From The Medical Birth Registry and The 
Registry of Legally Induced Abortions information about all births (live and stillbirths) 
and legally induced abortions with CPR number of mothers from 1973 to 1994 was 
obtained. From 1995, the National Patient Registry took over the registration from both 
registries and information was obtained through this registry. We obtained permission to 
link and store these data from the Danish Data Protection Agency. 
 
Studies of birth cohort effects in hormone levels 
In order to test the hypothesis that the discrepancy in the age related decline in serum 
testosterone between cross-sectional and longitudinal studies might be due to a 
population-level decline in male serum testosterone, serum samples were analysed from 
large population-based surveys conducted in Denmark and Finland. In total serum 
samples from 5350 Danish and 3270 Finnish men, who participated in large population 
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studies conducted in Denmark between 1983-1999 and in Finland between 1972-2002, 
were analysed for the concentration of testosterone. In addition samples were also 
analysed for LH and SHBG. LH secreted from the pituitary stimulates the production of 
testosterone in the LC. Testosterone on the other hand exerts a negative feed back 
regulation on the secretion of LH. Thus the ratio between testosterone and LH provides 
additional information about the function of the stimulated LC. In the circulation the 
majority of testosterone is bound to sex hormone binding globulin and only the few 
percent free testosterone are considered to be biological active. Thus strong feed back 
mechanisms operate to sustain a balance between testosterone, LH and free testosterone, 
and any change in one of the hormones and binding proteins will affect the others. The 
concentration of free testosterone were calculated using the method by Vermeulen et al., 
(1999) and the T/LH ratio were calculated as testosterone (nmol/L)/LH (IU/L). A general 
linear model was used to investigate the effect of age and period of birth (cohort effect) 
on the individual hormones and calculated ratios.  
 
Results 
Comparing male reproductive health in the former West and East Germany 
The former West and East Germany gives the unique situation of substantially different 
environmental exposure over the last 4-5 decades of genetically similar populations from 
which the state of male reproductive health can be assessed. In total 1,004 men were 
initially included into the study. However, 213 were excluded because either they or their 
mothers did not meet the eligibility criteria for place of birth. Thus, results of examination 
of 791 men are reported here; 334 from Hamburg, and 457 from Leipzig. The study 
period in Hamburg was February 2003 - July 2004, and in Leipzig July 2003 - April 
2005. 
 
Multivariate regression analyses were carried out to compare the two German groups of 
men and estimate the general level of each group for semen and hormone levels. In the 
final model duration of ejaculation abstinence was included as confounder for semen 
volume, sperm concentration and total sperm count, recent fever for all semen parameters 
and SHBG level, and hour of blood sampling in the analysis of hormone levels. The final 
models were subjected to standard checks of the residuals. Possible confounding factors 
affecting semen and hormone parameters were tested. The age of the man, his year of 
birth, season of year, recent fever and duration of abstinence were tested for confounding 
effects on semen and hormone parameters. Additionally, the effect of duration from 
ejaculation to assessment of motility was tested for effect on motility parameters and hour 
of day of blood sampling for effect on sex hormone levels. The effects of the possible 
confounders and effects of possible self-reported diseases and findings at physical 
examinations were tested in a multiple linear regressions analysis, and also taking 
possible interactions into account. 
 
No significant differences were observed for sperm concentration and total sperm count, 
whereas the differences for semen volume, sperm motility and morphology were 
significantly different between men from the two areas; higher frequency of 
morphologically normal forms and higher semen volume in the Hamburg group and 
higher frequency of motile spermatozoa in the Leipzig group (Table 3).  
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Table 3 Semen parameters of young German men from Hamburg and Leipzig 
 
  Observed Adjusted  
Difference 
between groups
  Mean (SD) Median (5-95) Median (95%CI)   
Semen volume (ml)      
Hamburg  3.4 (1.8) 3.2 (1.0-6.4) 3.4 (3.1-3.6)  p<0.0005 
Leipzig  2.7 (1.5) 2.6 (0.8-5.4) 2.8 (2.6-3.0)   
Motile sperm (%)      
Hamburg  66 (12) 68 (4.-80) 67 (65-69)  p<0.0005 
Leipzig  77 (19) 82 (36-95) 81 (80-81)   
Sperm concentration (mio/mL)     
Hamburg  63 (49) 49 (3-186) 46 (39-54)  p=0.4 
Leipzig  65 (57) 45 (6-174) 42 (36-50)   
Total sperm count (mio)     
Hamburg  206 (231) 142 (10-609) 154 (129-184)  p=0.3 
Leipzig  166 (166) 113 (10-476) 141 (118-168)   
Morphologically normal forms (%)    
Hamburg  9.3 (5.4) 8.5 (1.5-19.2) 9.4 (8.9-10.0)  p=0.005 
Leipzig  8.3 (4.8) 8.0 (1.5-17.4) 8.4 (7.9-8.9)   
Observed: Results based on raw data. SD: Standard deviation. 5-95: 5th-95th percentile. 
Adjusted: Median and 95% CI (confidence interval) calculated for the individual groups by linear 
regression analysis. Sperm concentration and total sperm counts are adjusted to the reference laboratory 
level, and these variables and semen volume adjusted to a period of ejaculation abstinence of 96 hours. 
Additionally, recent fever is accounted for. See text for further explanation. 
 
For the hormones the inhibin-B level was significantly higher for the men from Leipzig 
and E2 and LH higher for men from Hamburg, whereas there was no difference in the 
Testosterone level (Table 4). Increasing duration of ejaculation abstinence had an 
increasing effect on semen volume, sperm concentration and total sperm count (all 
p=0.001) up to 96 hours where after no further effect of increasing abstinence could be 
detected. Thus, the presented values for these semen parameters are adjusted to an 
abstinence period of 96 hours. Recent fever had a reducing effect on all semen parameters 
except semen volume, however, with varying significance; p=0.05 for motility, p=0.06 
for sperm concentration, p=0.10 for total sperm count and p=0.02 for frequency of 
morphologically normal forms. Increasing hour of day had a decreasing effect on inhibin-
B (p=0.001) and testosterone (p=0.04) and an increasing effect on FSH (p=0.01). The 
presented values for the adjusted hormone levels are thus corrected to a blood sampling 
time as 10 am. No statistically significant effect of hour of the day could be detected for 
LH, E2 or SHBG. Additionally, recent fever had a reducing effect on the level of SHGB 
(p=0.004). 
 
This study shows that the semen quality of young men from the German general 
populations from Leipzig and Hamburg is at a low level, that there is no biologically 
relevant difference in semen parameters between the two groups and that their sperm 
counts are at the same level as young men from Denmark and Norway. The average 
German man did not reach the full fertile range as defined by Guzick et al., 2001 (sperm 
concentration above 48.0 mio/mL, more than 12 % morphologically normal spermatozoa, 
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and more than 63 % motile spermatozoa) (Guzick et al., 2001) or thresholds measured in 
fertile men (Slama et al., 2002; Jensen et al., 2001).  
 
Table 4 Sex hormone levels of young German men from Hamburg and Leipzig 
 
 Observed Adjusted  
 Mean (SD) Median (5-95) Median (95% CI)  
Difference 
between groups
FSH (U/L)       
Hamburg 3.4 (2.1) 2.8 (1.1-6.9)  2.6 (2.4-2.8)        p=0.4 
Leipzig 3.2 (1.8) 2.8 (1.1-6.6)  2.7 (2.6-2.9)   
LH (U/L)       
Hamburg 4.2 (1.8) 4.0 (2.0-7.4)  3.9 (3.7-4.1)        p=0.001 
Leipzig 3.9 (1.6) 3.6 (1.7-6.5)  3.5 (3.4-3.7)   
Testosterone (nmol/mL)      
Hamburg 23.2 (9.3) 22.0 (11.9-38.1)  22 (21-23)        p=0.5 
Leipzig 23.6 (10.5) 22.4 (12.5-37.5)  23 (22-24)   
Estradiol       
Hamburg 87.8 (49.7) 82.0 (54.7-121.0)  83 (81-86)        p<0.0005 
Leipzig 79.8 (22.6) 77.0 (52.0-115.2)  77 (75-79)    
SHBG (nmol/L)       
Hamburg 29.5 (11.5) 28.0 (12.0-51.0)  28 (26-29)        p=0.5 
Leipzig 30.2 (11.7) 28.0 (13.9-53.0)  28 (27-29)   
Inhibin-B (pg/mL)       
Hamburg 184 (70) 178 (75-319)  176 (167-186)        p<0.0005 
Leipzig 209 (73) 203 (98-334)  203 (195-213)   
Observed: Results based on raw data. SD: Standard deviation. 5-95: 5th-95th percentile. 
Adjusted: Median and 95% CI (confidence interval) calculated for the individual groups by linear 
regression analysis taking hour of blood sampling as confounder into consideration. SHBG 
additionally adjusted for recent fever. 
 
Regional differences in male reproductive health and association with maternal 
exposure 
Between 1996 and 1999, semen quality of young men from five European countries (889 
from Denmark, 313 from Finland, 190 from Estonia, 157 from Lithuania, 221 from 
Norway) who were undergoing compulsory medical examination for possible military 
service were studied. Each man provided a semen sample, was examined by a physician, 
and, in collaboration with his mother, completed a questionnaire about general and 
reproductive health, current smoking habits, and exposure to smoking in utero. After 
adjustment for confounding factors, men exposed to smoking in utero had a reduction in 
sperm concentration of 20.1 % and a reduction in total sperm count of 24.5 % in 
comparison with unexposed men. Exposed men had a 1.15-ml (95 % CI: 0.66, 1.64) 
smaller testis size than unexposed men. The associations were present also when data 
from the study centres were analysed separately except for Lithuania, where only 1 % of 
mothers smoked during pregnancy. These findings strongly supported the hypothesis that 
foetal development is particularly vulnerable and important for adult reproductive health.  
Thus, maternal smoking may have long-term implications for the reproductive health of 
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the offspring and this further justifies the advice for pregnant women to avoid smoking 
(Jensen et al., 2004b).  
 
Secular trend in Finnish male reproductive health 
Semen quality of the Finnish men born at 1983 and examined during 2002-2003 showed 
an adverse trend when compared to previous cohorts studied in 1998-1999 (Jørgensen et 
al., in preparation). The median sperm concentration was only 47 million/mL that is 
similar to Danish figures while in the previous years the Finnish sperm concentrations 
were clearly higher (60) than Danish (47). The Finnish trend mirrors the increasing 
incidence of testicular cancer in the same age group of men, whereas in Denmark the 
increase in testicular cancer incidence appears to have levelled off and semen quality has 
remained unchanged over the last ten years. Thus, the difference in semen quality 
between Danes and Finns appears to vanish, and both share a serious problem in male 
reproductive health. Considering all cohorts of young men (n=4236) studied during the 
last ten years, semen quality in Finland (Turku) is still better than in Denmark 
(Copenhagen): median sperm concentration 46 million per ml in Copenhagen vs. 53 in 
Turku, total sperm counts 156 vs. 181 millions, respectively, and normal morphology (%) 
6.5 vs. 8.8, respectively. However, the recent decline in Finnish semen quality gives a 
new warning signal that reproductive health can be endangered in all parts of Europe. 
Analysis of the background data revealed that exposure to maternal smoking during 
pregnancy was associated with poor semen quality corroborating our previous findings 
and indicating foetal development as a vulnerable period. The data of the three 
longitudinal examinations of the men born in 1979-1981 showed unchanged semen 
quality indicating that one can already at the age of 18 or 19 years have a good estimate 
of lifetime semen quality. These figures are lower than those of fertile Finnish men and 
those published from other Finnish study groups previously, suggesting a clear decline.  
 
Declining trends in conception rates in recent birth cohorts of native Danish women 
We have analysed data from the Danish birth and abortion registries as well as the Danish 
registry for ART and defined a TNCR = fertility rate plus induced abortion rate minus 
ART conception rate. A unique personal identification number allowed the linkage of 
these databases. The database included 706,270 native Danish women born 1960 to 1980. 
We used projections to estimate the fertility of the later cohorts of women who had not 
yet finished their reproduction. We found that younger cohorts had progressively lower 
TNCR and that in terms of their total fertility rate the declining TNCR is compensated by 
an increasing use of ART.  
 
Assessing the validity of measured hormone levels and the influence of storage 
The validity of the samples on measured hormone levels was explored in three different 
ways. Firstly, a different aliquot of 434 of the samples had been analysed in 1994 and by 
the same laboratory, which allowed a direct comparison of the obtained hormone levels. 
For FSH, LH and SHBG the same assay formats were used in both measurements whilst 
testosterone and E2 used different assay formats. With an average ratio between the two 
measurements close to 1, there was no change in FSH, SHBG and testosterone after 10 
year period of storage (Table 5). The 12 % difference in LH levels was likely due to a 
long-term inter-assay variation, especially as the highest levels were measured in the 
aliquots that had been stored the longest. The mean ratio obtained for E2 is attributed to 
the different assay formats used. 
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Table 5 Correlation coefficient and mean ratio between the measurements analysed at 
the time of sampling in 1994 and after 10 years storage 
 
Hormone Correlation coefficient Mean ratios 
Follicle stimulation hormone (FSH) 0.991 1.04 
Luteinising hormone (LH) 0.977 0.88 
Sex hormone-binding globulin (SHBG) 0.980 1.04 
Testosterone 0.830 0.97 
Estradiol 0.680 1.18 
 
Secondly, several of the reproductive hormones are interrelated and therefore certain 
biologically determined correlations can be expected. The correlations between the five 
reproductive hormones for each sampling period were separately tested, as hormone 
degradation due to storage will be independent. The expected correlations (p<0.01) 
between the five reproductive hormones were consistently found in all four studies. 
 
Birth cohort effects for serum testosterone levels in individual regions of Europe 
Evaluation of the cross-sectional data indicates that, in addition to the well known age 
effect of falling testosterone levels with increasing age, an age-independent population-
level decline in testosterone levels seems evident with higher testosterone levels in the 
oldest cohort. A significant cohort effect was also observed for LH and SHBG with more 
recently born men having lower levels of all three hormones. Thus, Danish men born in 
the 1930ies had on average 19 % higher T, 28% higher LH, and 41 % higher SHBG 
levels than Danish men born between 1949 and 1954. Similar results were found for the 
Finnish men. In contrast, no cohort effect was evident for free T and T/LH levels 
suggesting that the cohort related changes in testosterone and SHBG were interrelated.  
We thus speculate that the secular decline in testosterone serum levels could be secondary 
to the decline in SHBG levels; simply adjusting the pituitary-gonadostat to a lower level 
in order to sustain the same level of free testosterone. The Danish and Finnish data could 
not be directly compared, as there was no overlap in the timing of collection of samples in 
the Danish and Finnish studies (Figure 13). 
 
 
Figure 13 Number and distribution of Danish and Finnish samples 
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The most pronounced cohort effect observed was for SHBG. The regulation of SHBG is 
complex and is not only dependent on the serum levels of testosterone and estrogen; the 
level of SHBG is also regulated by insulin and is often decreased in obesity. However, 
although adjusting for a concurrent increase in body mass index with later year of birth 
reduced the observed changes in testosterone this adjustment had only a moderate effect 
on the observed cohort related changes in SHBG levels. The observed age-independent 
changes in SHBG and testosterone may be explained by an initial change in SHBG levels, 
which subsequently lead to adjustment of testosterone at a lower level in order to sustain 
free testosterone levels.  
 
The aetiology behind the observed cohort effect remains to be resolved.  The cohort effect 
was most pronounced for the oldest cohorts. Thus, SHBG levels in the men born between 
1921-26>1931-36>1939-46>1949-56=1959-61=1969-70, indicating that whatever caused 
this cohort effect seems to have levelled out in the more recent cohorts. Large changes in 
lifestyle as well as in the environment occurred in Denmark during the 1900-century with 
a general significant increasing standard of life along with an increased industrialisation. 
A declining trend in male reproductive health manifested as an increase in testicular 
cancer and a declining sperm quality has been reported for the same period in many 
Western countries (Adami et al., 1994; Andersen et al., 2000; Carlsen et al., 1995; Møller 
et al., 1995; Swan et al., 2000). These adverse trends in male reproductive health and the 
observed changes in male reproductive hormone levels presented here could be 
interrelated. The cohort related changes in SHBG and testosterone serum levels did not 
lead to a change in the level of free testosterone, which is believed to determine the 
androgen activity. Nevertheless, a general decreased testosterone production will lead to 
lower intra testicular testosterone levels and thus, the paracrine effects of testosterone 
within the testes may be blunted. This is in line with previous findings of decreased serum 
SHBG and testosterone levels as well as decreased sperm concentration in men with 
BMI> 25 kg/m2 (Jensen et al., 2004a).  
 
Discussion 
No significant difference in semen concentration or total sperm count was found between 
young men from former West and East Germany when the data were adjusted for 
abstinence time, fever and inter lab variation. The sperm quality of young men from the 
former West and East Germany are similar to that observed in the Danish population. 
Young men from five European countries who have been exposed to smoking in utero 
have a reduction in sperm concentration after adjustment for confounding factors. The 
strength of association varies with the European country. Deterioration in Finnish male 
reproductive health has been observed with testosterone decreasing and SHBG increasing 
with age within the birth cohort. The semen quality of young men from the Finnish 
general population is much worse than that of partners of pregnant women (fertile 
population) and the difference between Denmark and Finland appears to decline. 
 
We found a progressively lower TNCR in the younger cohorts supporting our hypothesis 
of an ongoing birth cohort-related decline in fecundity. This hypothesis was also 
supported by our finding of increasing and substantial use of ART in the management of 
infertility of relatively young couples in the later cohorts. Furthermore, the lower rates of 
induced abortion among the younger birth cohorts, often viewed as a success of health 
education programs, may not be fully explained by improved use of contraception. It 
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seems more likely that decreased fecundity due to widespread poor semen quality among 
younger cohorts of otherwise normal men may explain some of the observed decline in 
conception rates.  
 
Sample storage and its influence of hormone measurement validity is an important 
requirement prior to hormone analysis. In the Danish and Finnish samples, a non-linear 
drop in testosterone levels with age was observed as well as a cohort effect with early 
cohorts tending to have higher levels (at the same age). Results on testosterone levels are 
in accordance with the hypothesis that decreased male reproductive health, which seem to 
be more frequent and is believed in many cases to be related to the foetal/neonatal 
development of the testis, also is reflected in decreased testosterone levels. This is in line 
with recently published data showing also a population-level decline in male serum 
testosterone levels in American men (Travison et al., 2007).  
 
Conclusions 
Danish and Finnish male reproductive health is in decline illustrating a secular trend. This 
also holds true for young men from the former West and East Germany, though a 
comparison between these two areas did not elicit significant differences. Foetal exposure 
to smoking has been highlighted as one reason for these observations in declining male 
reproductive health.  
 
Our finding of a declining TNCR among the young Danish cohorts imply that the current 
poor semen quality have an impact on the population fertility in the future – a situation 
which is difficult to reverse in the short term. The current and projected widespread use of 
ART may be a sign of such an emerging public health problem which also add to the load 
of medical costs in young population. It is not surprising that Denmark and Finland with 
their public health supported ART practices have the highest rate of pregnancies achieved 
with either in vitro fertilisation or intracytoplasmic sperm injection (Nyboe Andersen 
2006). It is of vital importance to continue surveillance of semen quality and all efforts 
should be made to identify the factors that may cause harm to be able to prevent further 
deterioration. 
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THEME 4 - LOW-DOSE AND MIXTURE EFFECTS OF EDC 
 
Overview and Objectives 
The EDEN project was motivated by the need to address major knowledge gaps relating 
to the low-dose issue and the problem of assessing EDC mixture effects. There were the 
following specific aims: 
 
Concerning EDC low-dose effects, EDEN aimed to 
 
• Systematically compare low-dose estimates derived from two-point comparisons 
(NOEL) with those produced by regression-based approaches. 
• Establish the shapes of dose-response curves in order to provide guidance for 
assessing the threshold issue. 
• Develop criteria for well conducted EDC studies that permit better estimations of 
low-dose effects. 
 
In relation to EDC mixture effects, the project aims were to investigate whether 
 
• The joint effects of EDC on cells, rodents or fish can be predicted from 
knowledge of their individual potencies. 
• Whether EDC produce observable mixture effects when combined at doses below 
their NOEL. 
• How EDC with different modes of action work together. 
• How knowledge about EDC mixture effects can be used productively in risk 
assessment. 
 
Materials and Methods 
A wide variety of assays, ranging from the cellular to the physiological level of biological 
complexity, was used to address the low-dose and mixtures issues: 
 
Stimulation of cell proliferation in ER-competent cells 
Induction of cell proliferation in estrogen-dependent tissues is considered to be the 
hallmark of estrogen action. Soto and Sonnenschein (Soto et al., 1995) have developed an 
assay based on human MCF-7 breast cancer cells that enables the detection of estrogenic 
agents. The cells depend on estrogens for survival, and the potency of an estrogenic 
chemical can be determined in terms of the number of cells that have appeared after a 
defined period of treatment. Throughout EDEN, a protocol described previously 
(Rajapakse et al., 2004; Soto et al., 1995) was employed and adapted to a miniaturised 
format using 96-well microtiter plates (Silva et al., 2007). 
 
Extended developmental toxicity assay in the rat 
Androgens are key regulators of male sexual differentiation during in utero and early 
postnatal development, both in humans and rodents, such as the rat. Exposure to 
chemicals that counteract androgen action at some stage in this period can permanently 
de-masculinise male foetuses and lead to malformations of the reproductive tract. 
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Reduced AGD, retention of nipples or areolas, hypospadias, agenesis of sex accessory 
tissues, and undescended testes in the male offspring have been described as 
consequences of disruption of androgen action in the developing rat. These effects are 
thought to arise through antagonism of androgens at the steroid receptor level and/or via 
suppression of testosterone synthesis in LC (Gray et al., 2001). 
 
To study the effects of antiandrogens and their mixtures in the rat, time mated 
nulliparous, young adult Wistar rats were dosed by gavage from early gestation through 
to the day before expected birth, and then from PND 1 until PND 16. The male offspring 
was examined for signs of disruption of male sexual differentiation by measuring changes 
in AGD, retained nipples and alterations in the weight of male accessory sex glands. 
Technical details concerning the quantitation of endpoints, dose-response analyses and 
assessment of mixture effects are described in Hass et al., (2007) and Metzdorf et al., 
(2007). 
 
Vitellogenin induction in zebrafish and sticklebacks 
In fish, synthesis of the egg yolk protein VTG is controlled by activation of the ER in the 
liver. Normally, male fish will not synthesise VTG, but it has been discovered that male 
fish exposed to estrogenic chemicals produce large quantities of the protein (Purdom et 
al., 1994). This phenomenon has been exploited as a sensitive biomarker for exposure to 
estrogenic agents, and was used as an endpoint for EDEN low-dose and mixture studies 
with two fish species, the zebrafish, and the stickleback. 
 
Fish were placed in tanks, and test chemicals delivered in continuous flow-through 
systems, as described by Brian et al., (2005) and Katsiadaki et al., (2006). VTG levels 
were determined by ELISA, and nominal concentrations of all tested chemicals were 
verified by chemical analysis.  
 
Spiggin induction in the stickleback 
Male stickleback synthesise large quantities of the glue protein spiggin during nesting. 
Spiggin induction is under the control of androgens. It is quite variable in male fish where 
it is influenced by light, social hierarchies and reproductive status. Female sticklebacks 
exposed to androgens also induce the protein, but the response is much more uniform. 
Antiandrogenic activities of test chemicals can be detected as a downturn in kidney 
spiggin levels in female fish co-exposed to a stable androgen (dihydrotestosterone) 
(Katsiadaki et al., 2006). 
 
Stickleback caught in European rivers were transferred to aerated aquaria and treated with 
test chemicals (flow-through systems) for 21 days. Spiggin analysis was performed by 
ELISA as described (Katsiadaki et al., 2002). Nominal concentrations of test chemicals 
were analysed by solid phase extraction, followed by GC/MS for nonylphenol, 
vinclozolin and fenitrothion and LC/MS for flutamide and linuron.  
 
Estimating low-dose effects: a methodological introduction 
What is “low-dose”? – Definitions. The term “low-dose”, as used in the context of EDC 
is not precisely defined. It is variously used to mean “doses lower than used normally in 
toxicity testing”, “doses that approach, or are equal to, those encountered by humans” and 
“doses associated with low effects”. For the purposes of EDEN low-dose studies, the 
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latter definition was adopted. Low effect doses signify doses producing small effects. 
Regardless of their nominal value, the challenge is to measure low effects, sometimes 
with the aim of establishing doses at the threshold between “effect” and “no effect”. 
 
Approaches to estimating low effect doses. Two major approaches to estimating doses 
“without effect” can be distinguished: multiple comparison procedures and regression 
model-based approaches. Multiple comparison procedures aim to establish a no-observed 
effect level (NOEL) on the basis of statistical hypothesis testing. A NOEL is defined as 
the highest tested dose that does not induce effects significantly different from untreated 
controls. Multiple comparison procedures do not make meaningful statements about the 
statistical inference of the outcomes (e.g. confidence belts) and the NOEL can only be a 
dose or a concentration that was actually tested. Regression model-based approaches 
tackle the problem from a different angle. Instead of making statements about doses 
where no effects could be observed, regression modelling attempts to estimate confidence 
limits that indicate whether effects observed with a certain dose are different from 
untreated groups. These methods estimate a dose that corresponds to a predetermined 
response level that is deemed acceptable (benchmark dose). Both these approaches have 
inherent strengths and weaknesses. 
 
Threshold concepts. NOEL are often wrongly equated with dose thresholds, toxicant 
doses that do not elicit any effects. It should be borne in mind, however, that NOEL are 
derived by hypothesis testing procedures. These examine whether the null hypothesis 
“controls and treated groups do not differ” can be rejected. A NOEL is the highest tested 
dose that did not produce a statistically significant effect. Only when the responses in the 
treated group exceed a certain limit (defined by significance criteria) can the hypothesis 
be rejected, and consequently, the tested dose is deemed as being larger than NOEL. 
However, this cannot be taken to mean that NOEL are devoid of effects. At and below 
NOEL, effects may either be truly absent or remain undetected, due to lack of statistical 
power. Therefore, rather than being a genuine reflection of zero effects, NOEL (“one of 
the most misunderstood notions in ecotoxicology”; Moore and Caux 1997) define a grey 
area, where it is impossible to distinguish whether effects are present or not. 
 
Slob (1999) has clarified the issue by introducing three different threshold concepts: 
 
• Seen from a mathematical point of view, a threshold is a dose associated with a 
zero response, and above which the response is larger than zero. 
• In an experimental or empirical sense, a threshold can be a quantitative estimate 
of a dose below which no effects can be observed within a given experimental 
setup (this is similar to NOEL).  
• The term can be taken to mean a biological threshold, in the sense of a dose below 
which the affected organism does not elicit any adverse effects. 
 
These three concepts are depicted in Figure 14. Mathematical thresholds in the sense of 
true zero effect levels cannot be determined empirically, because the statistical detection 
limit of the chosen experimental setup will always be a barrier. The empirical threshold 
concept is problematic in terms of risk communication. Whether an effect is observable 
depends on the sensitivity of the experimental design. With expenditure on more 
resources, the sensitivity of experiments can be increased considerably, with a downward 
shift in terms of doses deemed to be without effect. The biological threshold concept 
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would need to define the effect size deemed to be adverse, but absolute criteria to resolve 
this question are not available for EDC relevant endpoints.  
 
 
 
Figure 14 Three threshold concepts (adapted from Slob 1999). The shaded grey area 
defines the statistical detection limit of experiments used to derive estimates 
of doses “without effect”. Effects within this area cannot be distinguished 
with reliability from those seen with untreated controls. The experimental 
design should be chosen such that the minimum significant effect level is 
below the relevant effect size. 
 
Prediction and assessment of the effects of multi-component EDC mixtures 
It is often thought that the combined additive effect of chemicals is the simple sum of 
their individual effects at specific doses. The fallacy of this assumption becomes clear by 
considering two chemicals combined at doses that each produce saturation effects. The 
expectation that the joint additive effect should then be the sum of the individual effect is 
unrealistic when the individual effects are near the biologically maximally possible 
response. 
 
Thus, concepts better suited to dealing with chemicals that produce sigmoidal dose-
response curves are needed in calculating sound additivity expectations. Two 
pharmacologically sound concepts for the calculation of expected additive effects have 
emerged and are widely used: concentration addition (CA) and independent action (IA). 
CA assumes that chemicals act in a similar fashion, IA posits that mixture components act 
on different sub-systems in organisms, even though they may produce the same observed 
effects. Often, but not always, the two concepts produce different additivity predictions. 
 
Dealing with multi-component mixtures. Application of the two concepts to the 
assessment of multi-component mixtures requires that dose-response analyses of all 
individual mixture components are carried out to provide a basis for the calculation of 
expected additive effects for a mixture of specific composition (Fixed mixture ratio 
approach). The predicted mixture effects are then tested experimentally, and deviations 
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from expectation diagnosed as synergism or antagonism. EDEN has adopted this 
approach for all mixture studies. 
 
Experimental requirements: quantifiable endpoints. Dose-response analyses for both 
individual mixture components and the mixtures themselves are therefore a prerequisite 
for sound assessments of mixture effects. Thus, the endpoints chosen for analyses have to 
be readily and reproducibly quantifiable. Especially for in vivo studies this excluded 
endpoints that relied e.g. on the histological scoring of tissue slides. Quantification of 
effects also had to be achievable in a fairly cost and time effective way. The endpoints 
chosen for EDEN mixture studies lend themselves to quantification. They were: Cell 
number as measured by cell staining and then back-extraction, (quantification by 
measurement of optical absorbance in plate readers); determination of protein levels 
(VTG, spiggin) in the fish studies, by using ELISA (quantification in plate readers); 
measurement of AGD, counting of retained nipples, determination of organ weights, and 
quantitative determination of gene expression levels in the rat studies. 
 
Statistical and biometrical analyses. Statistical dose-response regression analyses were 
carried out by applying a best-fit approach (Scholze et al., 2001). Various non-linear 
regression models (logit, probit weibull, generalised logit I and II), which all describe 
monotonic sigmoidal dose-response relationships, were fitted independently to the same 
data set and the best fitting model was selected on the basis of a statistical goodness-of-fit 
criterion. As much as possible, data analysis was performed on pooled data from all the 
repeat studies. To account for the intra- and inter-study variability associated with this 
nested data scenario, the generalised non-linear mixed modelling approach was used, in 
which both fixed and random effects are permitted to have a non-linear relationship with 
the effect endpoint (Vonesh and Chinchilli 1996). NOEC and LOEC values were derived 
by testing a trend in dose or concentration effects against controls by using nonparametric 
multiple contrast tests (Neuhaeuser et al., 2000). 
 
Results 
The assays, chemicals and endpoints employed for low-dose studies in the EDEN project 
are listed in Table 6. 
 
Table 6 EDEN low-dose mixtures 
 
Assay Partner Chemicals Endpoint 
E-Screen 1 E2, β-HCH cell proliferation 
Developmental 
toxicity in the rat 
20 DINP, DEHP Changes in anogenital distance, 
nipple retention 
Zebrafish 13, 21 E2, E1, 
nonylphenol 
Vitellogenin induction 
Stickleback 2, 8, 19 E1, nonylphenol Vitellogenin induction 
Stickleback 2, 8, 19 Fenitrothion, 
flutamide 
Spiggin inhibition 
 
Non-monotonic dose-response curves were not observed 
None of the chemicals investigated in the endocrine disruption assays chosen for low-
dose studies exhibited dose-response curves with non-monotonic curvatures (inverted-U) 
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in the low-dose range. In some instances, a down-turn of responses from doses associated 
with a plateau was observed which could be attributed to cytotoxicity (e.g. in the E-
Screen assay). Concerns relating to the danger of overlooking effects at low-doses could 
not be confirmed. 
 
Shallow gradients in the low-dose range were common 
Instead, detailed low-dose response analyses revealed that many of the tested agents 
exhibited quite shallow curves in the low effect range, and this resulted in low-dose 
estimates with often surprisingly small numerical values. Figure 15 shows an example 
with E2 and the chlorinated hydrocarbon β-HCH in the E-Screen (Silva et al., 2007). 
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Figure 15 Concentration-response data and curves for E2 (closed circles, left plot) and 
β-HCH (open circles, right plot) in the E-Screen. For E2, the colours present 
data from different independent studies. The best-fitting regression models 
are shown as lines with the corresponding 95% confidence belt for the mean 
effect as dotted lines, with colours of lines corresponding to colours of data. 
The range of estimates for a concentration producing a 5% effect (EC05) is 
shown. For β-HCH (right), regression analysis (black open circles) yielded 
an estimate of 40 nM for a concentration producing a 1% effect. This was 
re-tested and confirmed directly with finely spaced concentrations between 1 
and 100 nM (green open circles) (Silva et al., 2007). 
 
Dose-response curves with small gradients give rise to complications during the 
estimation of low effect doses. High statistical power is necessary to arrive at valid 
estimates, and in this sense, the E-Screen serves as an illustrative example for the 
resources that are needed for the demonstration of effects with small magnitudes. 
Through using large sample sizes and numerous repeats, the experimental power of the E-
Screen was sufficiently high to measure effect magnitudes of around 1-2 % with 
reliability. However, such resources are usually not available for in vivo testing, with the 
consequence that the statistical detection limit is often considerably higher. If this 
coincides with shallow dose-response curves in the low effect range, the testing with only 
a few dose groups might fail to identify effects of a small size.  
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This dilemma is highlighted in Figure 16 with an example from an in vivo endpoint, 
suppression of spiggin induction by fenitrothion in female sticklebacks co-exposed to 
dihydrotestosterone. With the number of fish that could practically be used, and with the 
biological variation of the response, the statistical detection limit of the experiments did 
not allow reliable demonstrations of effects smaller than ca. 6% of the maximally 
inducible effect. Similar statistical detection limits were obtained with the other in vivo 
endpoints used for EDEN low-dose studies. This aspect of the EDC “low-dose” issue has 
not been appreciated sufficiently in the past. 
 
 
 
Figure 16 Reduction of maximally induced spiggin synthesis in the stickleback by 
fenitrothion. The shaded grey area highlights the statistical detection limit 
achievable within the experimental parameters. Effects of a magnitude of ca 
6% cannot be distinguished reliably from control responses. 
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Comparison of low-dose estimates derived by hypothesis testing and regression-
based approaches 
The optimisation of the E-Screen as a high through-put assay offered a model system in 
which various low-dose estimates could be compared directly by using large numbers of 
repeat studies (Figure 15). In extensive studies with 23 xenoestrogens (Silva et al., 2007) 
NOEL equated to effects of 1% in the E-Screen. 
 
Due to the lower statistical power achievable with the in vivo tests, NOEL were 
associated with larger effects of around 10% of a maximally inducible effect. For 
example, hypothesis testing methods yielded a NOEL of 0.1 µg/L for antiandrogenic 
effects of fenitrothion in the stickleback spiggin assay. However, regression analysis 
estimated that this concentration is likely to be associated with an effect of 6% (Figure 
16). Similar results, with often higher estimated responses corresponding to NOEL, were 
found with the other in vivo assays used in EDEN low-dose studies. These data showed 
very clearly, that NOEL cannot be equated with zero effect levels. 
 
Criteria for well conducted low-dose studies 
For each assay, detailed recommendations for low-dose studies were made, in terms of 
number of positive and negative controls, spacing and number of dose groups for 
regression analyses, and dose group sizes for studies based on hypothesis testing. Because 
a wide variety of different dose-response curves occurred, no uniform dose-response 
regression model could be found that was suitable for EDC in all cases. This means that 
the best fitting model should be chosen from a pool of regression models (Scholze et al., 
2001). 
 
Combining both approaches 
With the recognition that doses associated with zero effects cannot be determined 
empirically, the aim of low-dose EDC testing can only be to derive estimates of doses that 
correspond to a specific effect magnitude. Thus, the starting point of low-dose testing 
strategies should be a decision about the effect size a low-dose experiment should be able 
to demonstrate. 
 
Only after such a choice has been made, can the strengths of hypothesis testing 
procedures (the ability to test certain doses with a large number of replicates) and those of 
regression-based approaches (the ability to assess effect trends) be exploited productively 
for low-dose testing. Key elements of an approach combining the strengths of hypothesis 
testing and regression methods were outlined (Scholze and Kortenkamp 2007). The 
proposed integrated procedure aims to (1) identify the minimum effective dose that is 
statistically significant and produces an effect that it is at least of the relevant effect size 
and (2) if reliable, to estimate the corresponding dose for this effect size (benchmark). 
Firstly, a power analysis is performed with the aim of assessing whether the suggested 
experimental design is of sufficient sensitivity to demonstrate effect sizes of relevance. 
This can be achieved by comparing the statistical detection limit that is achievable with 
the chosen experimental design with the magnitude of the effect of relevance. 
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The effects of multi-component EDC mixtures were predictable by using 
concentration addition 
A large number of mixture studies were conducted as part of the EDEN project. The 
principal aim of these studies was to assess whether the joint effects of mixtures of EDC 
can be predicted accurately over a large effect range on the basis of dose-response data of 
the individual components. If there are demonstrable regularities between the potency of 
individual chemicals and the ways in which they act together, powerful tools for 
prospective risk assessment could become available. These tools could open the way to 
make productive use of existing single chemical data bases for the prediction of mixture 
effects. Table 7 gives an overview of the EDEN mixture experiments, the endpoints used 
and the chosen mixture components. 
 
Table 7 EDEN mixture studies 
 
Assay Partner Mixtures Number of 
tested mixtures 
Endpoint 
E-Screen 1 Up to 22 
estrogenic 
chemicals, 
combined with 
PCBs 
10 cell proliferation 
Developmental 
toxicity in the 
rat 
20 Vinclozolin, 
flutamide, 
procymidone; 
DEHP, 
finasteride, 
vinclozolin, 
prochloraz 
2 Changes in 
anogenital distance, 
nipple retention, 
reproductive organ 
weights 
Zebrafish 13, 21 E2, E1, EE2, 
nonylphenol 
1 Vitellogenin 
induction 
Stickleback 2, 8, 19 E2, E1, EE2, 
nonylphenol 
1 Vitellogenin 
induction 
Stickleback 2, 8, 19 Fenitrothion, 
flutamide, 
linurone, 
vinclozolin, E2, 
E1, EE2, 
nonylphenol 
6 Suppression of 
Spiggin induction  
Or spiggin 
inhibition 
 
Xenoestrogens in the E-Screen 
Development of a miniaturised format of the E-Screen (Silva et al., 2007) allowed high 
throughput screening and this made it possible to conduct by far the largest mixture 
experiments of the EDEN project. The 22 chemicals listed in Table 8 were combined at a 
mixture ratio proportional to the individual potency of each agent.  
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Table 8 Chemicals included in E-Screen mixture studies 
 
Groups Compounds Groups Compounds 
Endogenous hormones  Plasticisers  
 E2  Bisphenol A 
 E1 Preservatives  
Phytoestrogens   Butylparaben 
 Genistein  Propylparaben 
Pesticides  UV filters  
 o,p’-DDT  3-BC (Unisol S-22) 
 p,p’-DDT  4-MBC (Eusolex 6300) 
 o,p’-DDD  OMC (Eusolex 22920) 
 p,p’-DDE Musks  
 Endosulfan I  AHTN (Tonalide) 
 Endosulfan II  HHCB (Galaxolide) 
 Methoxychlor   
 Dieldrin   
 Aldrin   
 β-HCH   
 
On the basis of best-fit regression models (Figure 17) for all chemicals, an expected dose-
response curve was calculated by using CA, and this prediction was tested 
experimentally.  
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Figure 17 Concentration-response curves for 22 xenoestrogens and steroidal estrogens 
tested in the E-Screen assay. This information was used to calculate 
additivity expectations (see Figure 18). 
 
The data shown in Figure 18 show that prediction and observation agreed very well 
demonstrating that the joint effect of the 22 estrogenic agents was (concentration) 
additive. When tested in combination with xenoestrogen mixtures dioxin-like PCBs 
suppressed cell proliferation in the E-Screen. 
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Figure 18 Predicted and observed effects of a mixture of 21 xenoestrogens in the E-
Screen assay. 
 
Antiandrogens in an extended rat developmental toxicity model.  
The ability of a mixture of three androgen receptor antagonists to induce disruption of 
male sexual differentiation after in utero and postnatal exposure was investigated. 
Vinclozolin, flutamide and procymidone were administered by gavage to time mated 
nulliparous, young adult Wistar rats from gestational day 7 to the day before expected 
birth, and from PND 1 to 16. Changes in AGD, nipple retention (NR), and organ weights 
of accessory sexual glands in male offspring rats were chosen as endpoints for extensive 
dose-response studies with the individual mixture components (Figure 19). 
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Figure 19 Effects of vinclozolin, flutamide and procymidone, given individually, on 
AGD (left) and NR (right). Results shown are group mean ± standard error 
(red),  litter means from the dose-response studies (black), litter means from 
the single doses within mixture study (grey) and the mean dose-response 
curve ± 95% confidence belt based on regression analysis (blue) (Hass et al., 
2007). 
 
Vinclozolin, flutamide and procymidone were combined at a mixture ratio proportional to 
their individual potencies for causing retention of 6 nipples in male offspring. With AGD 
as the endpoint, the joint of effects of the three antiandrogens were essentially dose-
additive (Figure 20). However, the observed responses for NR were slightly higher than 
those expected on the basis of dose addition. A detailed account of these studies has been 
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published by Hass et al., (2007). Joint effects were essentially dose-additive with changes 
in the organ weights of accessory sexual glands as the endpoint (Metzdorf et al., 2007). 
 
 
 
Figure 20 Effects of mixed exposure to vinclozolin, flutamide and procymidone on 
AGD (left) and NR (right). Results shown are group mean ± standard error 
(red),  litter means (black), mean dose-response curve ± 95% confidence belt 
based on regression analysis (blue) and mean predicted mixture effect ± 
95% confidence belt (green) (Hass et al., 2007). 
 
A second mixture composed of antiandrogens with differing modes of actions (inhibition 
of androgen action by interfering with steroid synthesis, inhibition of steroid-converting 
enzymes and androgen receptor antagonism) was also tested. The phthalate DEHP, 
vinclozolin, finasteride and prochloraz were subjected to indepth dose-response analysis, 
both singly and in combination. In this case, anticipated additive effects calculated by 
using IA and CA yielded very similar predictions. They agreed well with the observed 
effects on anogenital index and NR. 
 
Estrogenic agents in zebrafish and sticklebacks 
A combination of E2, E1, EE2 and nonylphenol was examined in zebrafish and 
sticklebacks with VTG induction as the endpoint. With both fish species, the joint effect 
of the estrogenic chemicals was predicted well by using the concept of CA. 
 
Antiandrogens in the stickleback 
The antiandrogens fenitrothion, flutamide, linuron and vinclozolin were able to suppress 
androgen-induced spiggin synthesis in female sticklebacks. When administered together, 
the four chemicals produced concentration-additive mixture effects in this in vivo model. 
From in vitro studies with antiandrogens in gene reporter assays, it has been known that 
many estrogenic chemicals also function as androgen receptor antagonists. Considering 
these effects, it became an attractive proposition to test estrogens for antiandrogenic 
responses in the stickleback model. E2, E1, EE2 and nonylphenol produced reductions in 
spiggin synthesis in female sticklebacks. In combination, their effects were predicted 
fairly accurately by using CA. Finally, the mixture of four antiandrogens was combined 
with the four estrogenic agents to produce a mixture of eight chemicals. The joint 
antiandrogenic effects of this mixture agreed well with the additivity expectation 
according to concentration addition. 
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EDC produce mixture effects when combined at low-doses, below NOEL 
The extensive dose-response analyses conducted with vinclozolin, flutamide and 
procymidone allowed estimations of their NOEL with changes in AGD in the rat as the 
endpoint (Figure 21). When the three antiandrogens were combined at doses equivalent to 
their NOEL, significant reductions of AGD, equivalent to a 50% effect, were observed 
(Hass et al., 2007). Similar effects were also seen with changes in the organ weights of 
accessory sexual glands as the endpoint (Metzdorff et al., 2007).  
 
 
 
Figure 21 Mixture effects on AGD at low-doses of individual mixture components. 
Results shown are group means ± 95 % confidence intervals for control 
males and females (grey), individual doses of 24.5 mg/kg vinclozolin (VZ), 
0.77 mg/kg flutamide (FLUT) and 14.1 mg/kg procymidone (PRO) (red), 
the combined mixture dose of 39.37 mg/kg (red) and the predicted mixture 
effect (green). Open circles represent litter means. * p < 0.05 compared to 
control (Hass et al., 2007). 
 
Suppressions of androgen-stimulated spiggin synthesis equivalent to a 30 % effect were 
found in the stickleback with vinclozolin, flutamide, linuron and fenitrothion at 
concentrations that by themselves did not produce responses statistically significantly 
different from controls. 
 
Finally, information about blood serum and adipose tissue levels of xenoestrogens in 
European women was compiled (also using data emanating from EDEN Theme 1 work) 
to conduct a mixture experiment in the E-Screen at environmentally relevant 
concentrations. At the serum concentrations, the effects of most of the individual 
xenoestrogen were far too small to be measurable in the E-Screen. Combined at average 
European pollution levels, the impact of 19 xenoestrogens, for which exposure data were 
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available, on the effects of physiological levels of E2 and E1 was negligible. However, a 
composition modelled on more severe pollution levels found in certain South European 
countries revealed a significant additional combined effect load of the xenoestrogens. 
 
Elements of an EDC mixtures risk assessment approach 
Risk assessment approaches that take account of EDC mixture effects need to address 
three fundamental issues: 
 
• What is the likelihood of synergistic combination effects and which parameters 
are important in increasing the chance of synergisms? 
 
• Is it possible to adopt a default concept in predicting additive combination effects? 
 
• What are determinants of additive mixture effects of EDC? 
 
In principle, synergisms (or antagonisms) may occur when there are toxicokinetic 
interactions between mixture components. For example, one component may facilitate 
effective transport of another to target sites and in this way lead to greater effects than 
anticipated. Similarly, differential induction of toxifying (or detoxifying) steps will 
produce combination effects that differ substantially from additivity expectations. 
Although the available evidence suggests that EDC mixture effects are (dose) additive 
(Kortenkamp 2007), there are uncertainties about the likelihood of synergisms because 
mixtures where there is a reasonable chance of synergisms occurring have not been tested 
sufficiently. In the future, work should be undertaken to systematically explore the 
potential for synergisms, and this has to focus on the possibility that chemicals devoid of 
endocrine activity may lead to significant exacerbations of EDC mixture effects. A viable 
option of dealing with this uncertainty is to adopt an additional safety factor for EDC. 
 
The published record in the literature shows that the effects of combinations of EDC 
belonging to a similar class do not deviate substantially from dose addition. Until 
evidence to the contrary emerges, dose (or concentration) addition can therefore be 
adopted as the default concept for risk assessment of EDC mixtures. 
 
Four factors strongly determine the magnitude of combination effects to be expected from 
a mixture: The number of chemicals involved, their potency, their relative prevalence 
(mixture ratio) in the mixture and their total dose. Thus, mixtures composed of chemicals 
present at low-doses and with a low potency, can nevertheless induce significant 
combination effects if exposure is to a sufficiently high number simultaneously. 
 
However, incomplete knowledge about the identity of chemicals with endocrine 
disrupting potential is one of the major sources of uncertainty in EDC mixtures risk 
assessment. Low-dose and low potency of EDC alone are uninformative in risk 
assessment. The other key determinant that decides whether a mixture can be deemed safe 
(or unsafe) is the sheer number of EDC that make up a particular human or wildlife 
exposure scenario, and this information is currently either incomplete or does not exist. 
 
While the above data gaps should be filled as a matter of utmost urgency, satisfactory 
resolution of all uncertainties is not likely in the foreseeable future. On the other hand, the 
knowledge about determinants and factors that govern the joint action of similarly acting 
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EDC is sufficiently advanced to come to pragmatic risk assessment approaches. In the 
light of these considerations, a panel meeting with experts from EU environmental 
agencies and NGO’s has proposed the following modus operandi for EDC mixtures: 
 
• In particularly “data-rich” situations, where both exposure information and low-
dose estimates are known, it is proposed to use the concept of dose addition 
(including the TEF approach) to arrive at a “mixture no-observed-adverse-effect-
level” (MNOAEL) for endpoints relevant to endocrine disruption. These are then 
combined with a safety factor to arrive at estimates of tolerable human exposure. 
 
• In “data-poor” situations, where there is fragmentary information about the 
number of chemicals with endocrine activities, their exposure levels, their 
potency, and their effects at low-doses, except for a few “prototype” chemicals, it 
is proposed to estimate a crude MNOAEL by dividing the individual NOAEL of 
the “prototypical” chemical by the anticipated number of relevant similarly acting 
chemicals. This will be based on chemicals where information about relevant in 
vivo effects is documented. If this information is not available, then additional 
chemicals should be “ruled in” on the basis of in vitro test results. If the number of 
chemicals contributing to mixture effects is unknown, it is suggested to choose a 
default number in the region of 10-20 until evidence to the contrary emerges. The 
resulting MNOAEL is then combined with the usual assessment factor (e.g. 100) 
to estimate tolerable levels for human exposure. 
 
Discussion 
The EDEN project has produced a wealth of new information about EDC low-dose 
effects and about the ways in which EDC act together in combination. 
 
The experiments carried out to address the “low-dose” issue have not produced new 
examples of non-monotonic dose-response curves in the low-dose range. Instead, it was 
discovered that EDC exhibit dose-response curves with shallow gradients in the low-dose 
range. In these situations, the customary reliance of safety evaluations on estimating 
NOEL increases the likelihood of overlooking effects. 
 
The mixture studies have shown that valid predictions of the effects of multi-component 
mixtures of EDC can be made in in vivo assays with endpoints of toxicological relevance. 
When sufficiently large numbers of EDC are combined, and when the statistical detection 
limit of the assay is sufficiently high, then joint effects of EDC can be demonstrated at 
doses below their individual NOEL. Such demonstrations heighten the need for taking 
mixture effects into consideration during risk assessment. 
 
Conclusions 
The application of hypothesis testing methods is inadequate for capturing low-dose 
effects of EDC. Whenever possible, regression-based approaches with their benchmark 
dose limits should replace NOEL as the basis for establishing acceptable human exposure 
levels. Ideally, hypothesis testing and regression methods should be combined in a 
framework that utilises the strengths of both methodologies by making considerations of 
statistical detection limits and statistical power the starting point of testing procedures. 
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Implementation of this framework will require a significant change in toxicological 
testing practice. 
 
Determinants of additivity for EDC mixtures have been characterised and are now well 
understood for combinations of similarly acting EDC. EDC of relatively low potency and 
at low exposure levels can still work together to produce significant combination effects 
when they are present in sufficient numbers. In cases where EDC act in concert with 
endogenous hormones, this may result in significant additional effects under certain 
circumstances. 
 
Uncertainty still exists in relation to the likelihood of synergistic mixture effects, and 
concerted efforts should be made to fill this gap. Another source of uncertainty that will 
hamper sound EDC mixture risk assessment is incomplete knowledge about the identity 
of EDC, their exposure levels and number. This issue can only be resolved through the 
development of dedicated exposure assessment strategies that take account of cumulative 
exposures. 
 
Despite some knowledge gaps concerning exposure estimations and the likelihood of 
synergisms, knowledge about determinants and factors that govern the joint action of 
similarly acting EDC is now sufficiently advanced to come to pragmatic risk assessment 
approaches to take mixture effects into consideration. Elements of a modus operandi for 
EDC mixtures include the use of dose addition (including the TEF approach) to arrive at a 
MNOAEL for endpoints relevant to endocrine disruption. These are then combined with a 
safety factor to arrive at estimates of tolerable human exposure. “Data-poor” situations 
may require estimation of a crude MNOAEL by dividing individual NOAEL of certain 
prototype chemicals by the anticipated number of relevant similarly acting chemicals. 
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Conference Presentations 
For a full listing of presentations given at conferences and meetings, please refer to the 
Scientific Annual Reports. To illustrate the wide representation EDEN has had at 
numerous conferences over the past 4.5 years, a selection of conferences attended by 
several of the Partners is given below: 
 
Bourguignon JP The impact of endocrine disrupting chemicals on female puberty. 
Presented at the Annual Endocrine Society meeting in Toronto, June 2007 (By 
Invitation). 
 
Cheshenko K, Molecular Research in Environmental Medicine, 2nd International 
Conference, Paris, France. September 2006 
 
Christiansen S & Hass U (2006) Mixture effects of antiandrogens in rat male offspring:  
Effects on anogenital distance, nipple retention, external and internal male reproductive 
organs. Oral presentation at EDEN forum meeting, Granada, Spain 
 
Eggen R, Cheshenko K, Neuhauss,S, and Segner H. The production of transgenic 
zebrafish that respond to EDC. Prague, Czech Republic 10-12 May 2005. 
 
Eggen R, Kallivretaki E, Cheshenko K, Neuhauss S, and Segner H. Mechanisms of 
endocrine disruption in zebrafish. Cadro, Switzerland, 2005. 
 
Gomes RL, Kortenkamp A, 2006. Progress in the garden of EDEN. Presented at the 
Gordon Research Conference Environmental Endocrine Disruptors, Il Ciocco, Italy. 4-9 
June 2006 (By Invitation) 
 
Sharpe RM, ‘Animal models for testicular dysgenesis syndrome’1st International 
Conference on Urogenital Disorders. Malmo, Sweden, September 2005 (By Invitation) 
 
Sharpe RM, ‘Use of an animal model to study the foetal origins of the commonest 
reproductive disorders in newborn and young adult males’. Gordon Research Conference 
on ‘Environmental endocrine disruptors’. Il Ciocco, Italy June 2006 (By Invitation) 
 
Sharpe RM, ‘Foetal and early postnatal origins of environmental reproductive health 
effects in the male’. UCSF-CHE Summit on Environmental Challenges to Reproductive 
Health and Fertility. January, San Francisco, USA January 2007 (By Invitation) 
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Hass U, Filinska M, Kledal TSA (2003). Antiandrogenic effects of diisononyl phthalate 
in rats. Poster at 31st Conference of European Teratology Society, Denmark. Abstract in 
Reproductive Toxicology 2003, 17, 493-494. 
 
Hass U (2003). Effects on sexual dimorphic behaviour in rats after developmental 
exposure to anti-androgens. Invited speaker at 31st Conference of European Teratology 
Society, Denmark. Abstract in Reproductive Toxicology 2003, 17, 482. 
 
Hass U (2003). How do current regulatory test methods for chemicals cope with late 
effects and vulnerable windows in reproductive toxicology? Invited speaker at European 
Environmental Agency Meeting "Reproductive Toxicology and Chemicals: a matter of 
timing?", Copenhagen, October 2003.  
 
Hass U (2004). The role of in vitro and in vivo screening assays in prioritising testing 
strategies – are we using the right tools? Speaker at EURISK/CREDO Cluster Workshop 
on “Multiorganic Risk Assessment of Endocrine Disruptors”, Mallorca, Spain, March 
2004. 
 
Hass U (2004). Mixture and low-dose effects in rats after pre- and postnatal exposure to 
EDCs. Speaker at EDEN Planning Meeting, Mallorca, Spain, March 2004 
 
Hass U, Filinska M, Pedersen S, Dalgaard M, Kledal TSA (2004).  Effect of finasteride 
and DEHP on anogenital distance and nipple retention after perinatal exposure in rats. 
Poster presented at the European Teratology Society Conference, September 2004, 
Greece. Abstract in Reprod Toxicol 2004.  
 
Hass U, Christiansen S, Axelstad M, Scholze M and Kortenkamp A (2007). Combined 
exposure to dissimilarly acting antiandrogens causes markedly increased frequency of 
hypospadias in the rat. Poster at 4th Copenhagen Workshop on Endocrine Disrupters, 
Denmark 
 
Jolly C, Katsiadaki I, Le Belle N, Mayer I and S. Dufour (2006) Development of a 
stickleback in vitro assay for the rapid screening of (anti-)androgenic Environmental 
contaminants. 23rd Conference of European Comparative Endocrinologists, Manchester, 
UK, September 2006 
 
Katsiadaki I, Sebire M, Scott AP, Geoghegan F, Katsu Y, Iguchi T, Nagae M (2005) The 
stickleback model in endocrine disruption research: a progress report within the UK-
Japan co-operation. The 7th Scientific Workshop of the UK-J Research on Endocrine 
Disrupters, Okinawa, Japan, 2nd-3rd December 2005  
 
Katsiadaki I, and Scott AP, (2005). The stickleback model in endocrine disruption 
research: an essential tool in the laboratory and field. PRIMO 13, Alessandria, June 2005 
 
Katsiadaki I, Allen Y, and Scott AP, (2005) The three-spined stickleback as a sentinel 
organism for evaluating the effects of endocrine disrupters: a progress report.. SETAC 
Europe, 15th annual meeting, Lille, France, May 22-26,  
2005  
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Katsiadaki I, and Scott AP, (2004). Is the humble stickleback one of the best model 
species to study the effects of xenobiotics with endocrine modulating activity?. The 5th 
International Symposium on Fish Endocrinology, Castellon, Spain, September 5-9, 2004  
 
Katsiadaki I, and Scott AP, (2004) The stickleback model: From lab to field. CREDO 
workshop on Endocrine Disruptors, Exeter University, July 2004  
 
Katsiadaki I, (2004).  Simultaneous assessment of oestrogenic and (anti)-androgenic 
effects using the three-spined stickleback. UK-Japan Workshop on endocrine disrupters, 
19 February 2004, Kumamoto, Japan. 
 
Katsiadaki I, Mayer I, and Scott AP, (2003) The three-spined stickleback as the European 
sentinel and a model species for endocrine disruption research. The 4th International 
conference on Stickleback Behaviour and Evolution, Sweden 
 
Katsiadaki I, Scott AP, and Mayer I, (2003) The three-spined stickleback as a model for 
the detection of (anti)-androgenic and oestrogenic xenobiotics. SETAK UK conference, 
York, April 2003 
 
Sanders MB and Katsiadaki I (2006).  Stickleback biomarkers and behaviour as sensitive 
indicators of exposure to, and effects of, steroids and pharmaceuticals. Risk Assessment 
of Pharmaceuticals & Veterinary Medicines in the Environment Conference, 26-27 
September 2006, Amsterdam, The Netherlands 
 
Sanders M, Katsiadaki I (2006) The stickleback model in ecotoxicology: an essential tool 
in the laboratory and the field. Fifth International Conference on Stickleback Behaviour 
& Evolution, Anchorage, Alaska 30th July - 4th August 2006 
 
Sebire M and Katsiadaki I (2006) The effect of endocrine disrupting chemicals that 
interfere with androgen action on the reproductive behaviour of the three-spined 
stickleback. The 5th International Conference on Stickleback Behaviour and Evolution, 
Anchorage, Alaska, 30th July - 4th August 2006  
 
Toppari J, Regional and temporal trends in the prevalence of cryptorchidism and 
hypospadias. In the International Symposium on Endocrine Disrupters, 25.-28.11.2002, 
Hiroshima, Japan. 
 
Toppari J, Trends in hypospadias and cryptorchidism in Europe. In the 2nd Copenhagen 
Workshop on Endocrine Disrupters: A possible role of mixed exposures for reproductive 
failures and malignancies, 7.-9.12.2002, Copenhagen, Denmark. 
 
Toppari J, Timing of puberty, In the Nordic Network of Pediatric Endocrinologists, 20-
23.11.2003, Reykjavik, Island 
 
Toppari J, Prevalence of genital malformations in male newborns: in Finland. In the 
Environmental Disrupters and Pediatric Endocrine Diseases, 12-13.12.2003, Montpellier, 
France 
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Toppari J, Cryptorchidsm as a part of testicular dysgenesis syndrome. In the CREDE 
(Turku)-IRDB meeting, 21-22.4.2004, London, U.K. 
 
Toppari J, Nordic differences in testis development and its disorders. In the 13th 
European Testis Workshop, 24-28.4.2004, Dunblane, Scotland 
Toppari J, Trends of male reproductive health in Nordic countries. In the 6th Congress of 
the Hellenic Andrology Society, 5-6.11.2004 Thessaloniki, Greece 
 
Toppari J, Regional and temporal differences in the prevalence of cryptorchidism and 
hypospadias: ecological differences in exposure to organochlorines and pesticides. In the 
Copenhagen Workshop on Environment, Reproductive Health and Fertility, 15-
18.1.2005, Copenhagen, Denmark 
 
Toppari J, Endocrine disrupters and sexual precocity. In the 2nd European Congress on 
Diagnosis and Treatment of Central Precocious Puberty, 1st International Symposium on 
Growth Hormone Treatment in Short Children: State of the Art, 17-18.3.2005 Pisa, Italy 
 
Toppari J, Differences in male reproduction health between Denmark-Finland: effects of 
neonatal exposures. In the CREDO Workshop on Endocrine Disrupters: Exposure 
Assessment, Epidemiology, Low-dose and Mixture Effects, 10-12.5.2005, Prague, Czech 
Republic 
 
Toppari J, Incidences, regional differences and temporal changes in occurrence of 
hypospadias. In the NAFA Workshop on Hypospadias and Leydig Cell, 30.9-1.10.2005, 
Copenhagen, Denmark 
 
Toppari J, Male reproductive health in Europe - Cryptorchidism and hypospadias. In the 
Workshop on the Development and Function in Adulthood of the Male Reproductive 
System  Potential Chemical-induced Effects, 15.2.2006, York, UK. 
 
Toppari J, Mechanisms of male undermasculinisation. In the 20th Summer School of the 
European Society for Pediatric Endocrinology, 26-30.6.2006, Nunspeet, Holland 
 
Toppari J, Trends in congenital abnormalities of male reproductive system: possible role 
of endocrine disrupters. In the 45thAnnual meeting of the European Society for Paediatric 
Endocrinology (ESPE) on Pediatric Endocrinology: The impact of programming, 30.6-
3.7.2006, Rotterdam, The Netherlands 
 
Toppari J, The Finnish-Danish gradient in male reproductive health. In the Life Cycle of 
the Gonad symposium in honour of professor Niels E. Skakkebæk, 25.10.2006, 
Copenhagen, Denmark 
 
Toppari J, Biological and toxicological mechanisms leading to altered semen quality, 
with a focus on mechanisms relevant to environmental contaminants. In the International 
Workshop on Air Pollution and Human Reproduction. 9-11.5.2007 Munich, Germany 
 
Toppari J, Cryptorchidism up-date. In the Centre of Reproductive Medicine, Scanian 
Andrology Centre, Malmö University Hospital, Lund University. 15.5.2007 Malmö, 
Sweden 
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Toppari J, Male reproductive disorders in Nordic-Baltic area. In the 2nd Workshop on 
Reproductive Biomedicine. 17-19.5.2007, Tartu, Estonia 
 
Toppari J, Early signs of problems in male reproductive helth. In the XVIII annual 
meeting of Sociedad Chilena de Reproduccion y Desarrollo, 16-18.8.2007 Chillan, Chile. 
 
Toppari J, Endocrine disruption intruders. In the 1st Workshop on Environmental and 
Health. Capacity building for decision making, 17-21.9.2007 Kos, Greece. 
 
Press and Magazines 
Outcomes from EDEN have been widely publicised in the media and popular press. This 
has included television appearances on endocrine disruption and the mixture issue 
(Kortenkamp A, ITV, United Kingdom) and in vivo test methods used for assessing 
antiandrogenic effects in rats (Hass U, Arte, France). 
 
Newspapers throughout Europe have reported on many results arising from EDEN. 
Examples include: 
 
• Utilising the TEXB approach for EDCs pioneered by Nick Olea and colleagues 
(Spain). 
• Poor sperm quality and male reproductive health in Denmark and Finland and 
comparisons between these two countries as led by Niels Skakkebæk and 
colleagues (Denmark) and Jorma Toppari and colleagues (Finland). 
• Rat mixture studies showing marked adverse mixture effects at dose levels where 
the individual chemicals alone show no effects carried out by Ulla Hass and 
colleagues (Denmark). 
 
The popular scientific magazine, the New Scientist has often cited EDEN outcomes with 
two features referring to the work carried out by Manual Tena Sempere, Ulla Hass and 
Andreas Kortenkamp.  
 
As part of the International Conference entitled ‘Endocrine Disrupters: Exposure 
Assessment, Epidemiology, Low-dose and Mixture Effects’ organised by the EDEN and 
FIRE consortia, a press conference held in Brussels was organised and reported in the 
European press. 
 
Cluster of Research on Endocrine Disruption in Europe (CREDO) 
Brochure, Newsletters and Website 
A network of research called the Cluster of Research on Endocrine Disruption in Europe 
(CREDO) was established under the jurisdiction of the EDEN project 
(http://www.credocluster.info/intro.html). CREDO would facilitate effective research 
collaborations across a core of 4 projects (EDEN, COMPRENDO, EURISKED and 
FIRE) and a further 8 projects funded in the last round of the Fifth Framework 
programme. A brochure profiling CREDO was first available detailing the aims of the 
cluster and research programme (http://www.credocluster.info/docs/credobrochure.pdf). 
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Eight newsletters were published from September 2003 to November 2006 
communicating research features from the projects and information on workshops. The 
final double issue (7&8) provided summaries of the findings from these projects, along 
with the perspectives for environment and health research activity in the Seventh 
Framework Programme (FP7). 
 
EDEN Website 
A website was developed to inform the public and scientific community about the EDEN 
project and its progress. The site introduces the research area and the projects aims and 
research themes. The ‘Achievements’ section gives the publications arising from the 
EDEN project which number >100. The ‘what’s new’ section is continually updated 
including a section on the Prague Declaration on Endocrine Disruption which arose from 
the Workshop held in Prague 2005 and there is also a separate header with the complete 
document. As well as the summaries for each of the four yearly reports, a poster 
presented to the GRC on the activities arising from EDEN is available on the ‘what’s 
new’ section of the website. All eight issues of the CREDO Cluster newsletter are also 
available as pdfs on the main site, along with a synopsis of each issue. A separate part of 
the website is only accessible to EDEN members to aid communication. 
 
International Workshop ‘Endocrine Disrupters: Exposure Assessment, 
Epidemiology, Low-dose and Mixture Effects’ 
International experts and scientists representing many different disciplines came together in 
Prague on 10 – 12 May 2005 for a workshop on chemicals that interfere with hormone 
systems, so-called endocrine disrupters. The workshop ‘Endocrine Disrupters: Exposure 
Assessment, Epidemiology, Low-dose and Mixture Effects’ was organised by the EDEN 
and FIRE consortia and was convened to discuss recent European research on the health 
risks associated with these chemicals. At this international workshop, scientists from across 
Europe presented the latest research findings in endocrine disrupter research. Much of this 
work emanated from large research projects funded by the European Union, and joined 
together in the cluster for research on endocrine disrupters, CREDO. There were discussions 
to promote the transfer of know-how between scientists on the issues of exposure 
assessment, epidemiology, low-dose and mixture effects. The programme included sessions 
on male reproductive health in Europe, human and wildlife exposure to endocrine disrupters, 
novel endpoints and biomarkers, as well as on low-dose and mixture effects of endocrine 
disrupters and their assessment. The results presented at the Prague workshop have 
reinforced concerns over the long-term consequences of exposure to endocrine disrupters to 
humans and wildlife. Outcomes from the workshop resulted in a Special Issue in 
Environmental Health Perspectives which was available online from June 2007. The 
workshop also gave rise to the 'Prague Declaration on Endocrine Disruption' which has been 
signed by over 200 scientists (http://www.edenresearch.info/public/PragueDeclaration% 
2026%20May%202006.pdf). 
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Prague Declaration on Endocrine Disruption 
The Prague Declaration which to date has been signed by more than 200 scientists active 
in the field of endocrine disruption was unveiled at a press conference held in Brussels 
2005, the press release is given below: 
 
“EMBARGOED UNTIL 20 JUNE 2005 
PRESS RELEASE 
LEADING SCIENTISTS CALL ON EU TO TAKE ACTION ON HARMFUL 
CHEMICALS 
 
Brussels, 20 June 2005.   Leading scientists today called on the EU to take precautionary 
measures to protect humans and wildlife from chemicals that interfere with the hormone 
system, known as endocrine disrupters. 
 
More than 100 scientists actively working in research in this area in Europe and in the US 
have now signed the Prague Declaration on Endocrine Disruption which sets out latest 
research results in the area, as well as highlighting the shortcomings of the EU’s proposed 
REACH regulation for dealing with chemicals. 
 
“Recent research that has been carried out in Europe and in the US indicates that 
existing rules to protect babies and young children from certain chemicals are targeting 
the wrong life stage, “ said Dr Andreas Kortenkamp, coordinator for the EU-funded 
EDEN research project into endocrine disruption. “We need to protect pregnant women 
from exposure to these chemical substances so that we prevent genital abnormalities 
occurring in the developing foetus.” 
 
Endocrine disrupters are a diverse group of chemicals in everyday use, including some 
pesticides, flame retardants, pharmaceuticals and certain plasticisers or phthalates found 
in soft vinyl plastic toys and cosmetic ingredients, for example. 
 
At today’s press conference, Professor Niels E. Skakkebæck M.D, who coordinates 
EDEN’s research into human male reproductive health presented research detailing the 
high prevalence of reproductive disorders in European boys and young men and the rise 
in cancers of reproductive organs, such as breast and testis. “We have identified an 
extremely disturbing trend that shows a substantial rise in genital disorders in boys and 
young men in Europe,” said Professor Skakkebæck. “We need to make absolutely sure 
that research is constantly updated in this area.” 
 
Professor Dr Jörg Oehlmann is coordinating European research into wildlife effects 
produced by endocrine disrupters, as part of the EU-funded COMPRENDO project into 
comparative research on endocrine disrupters. “The severity of the endocrine disrupting 
effects we have observed in wildlife as a direct consequence of exposure to certain 
chemicals is a cause for concern amongst scientists around the world. We should 
remember that, while wildlife represents a protection target in its own right, it also 
provides early warnings of effects produced by endocrine disrupters which may as yet be 
unobserved in humans.” 
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Dr Kortenkamp warned that current proposals by the EU to regulate chemicals do not 
cover endocrine disrupting chemicals. “At the moment, REACH does not specify 
endocrine disrupting properties nor does it include clearly defined criteria to objectively 
identify substances with endocrine disrupting properties. This could mean that endocrine 
disrupters will fall outside of the EU authorisation process which would be a major 
obstacle to the efficient regulation of chemicals, and its intended role to protect humans 
and wildlife from harm.” 
 
ENDS 
 
NOTES FOR EDITORS 
At a recent meeting in Prague, European scientists working in this area agreed the Prague 
Declaration on Endocrine Disruption which now has over 100 signatories, including 
leading scientists from the US.  
 
The text of the Prague Declaration is accessible at http://www.edenresearch.info/ under 
the ‘what’s new’ section. The names of the scientists are also listed. 
 
In the past month, the results of more research into the area of endocrine disrupters have 
shown that exposure to certain chemicals in everyday use pose serious health concerns. 
These published scientific studies include research linking pregnant women’s exposure to 
phthalates and adverse effects on the genital development of their male children. A 
summary of recent scientific studies is included in the press pack. 
 
REACH is the proposed European regulation concerning the Registration, Evaluation, 
Authorisation and Restriction of Chemicals.” 
 
The Prague Declaration can be accessed from the EDEN website 
(http://www.edenresearch.info/declaration.html). It has had wide dissemination including 
a journal and broadsheet: 
 
• Europa research.  
http://europa.eu.int/comm/research/environment/newsanddoc/article_2826_en.htm 
• EPHA Environment Network. http://www.env-health.org/a/1821 
• Our Stolen Future. http://www.ourstolenfuture.org/Consensus/2005-
0620praguedeclaration.htm 
• ESPR – Environ. Sci. Poll. Res. 12 (4) 188 (2005). 
http://www.scientificjournals.com/sj/espr/Pdf/aId/7527 
• EMHF European Men’s health forum. 
http://www.emhf.org/index.cfm/item_id/291 
• Guardian June 20 2005 
http://www.safecosmetics.org/newsroom/the_guardian_6_20_05.cfm 
• EUROPEAN WATER MANAGEMENT NEWS, 3 august 2005 
http://www.nwp.nl/objects/EWMN%203%20August%20-%202005.doc 
• PAN issue no 23 July – august 2005 http://www.pan-
europe.info/newsletter/news23.shtm 
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Expert Panel Workshop on the Options for Incorporating Knowledge 
and Low-dose and Mixture Effects in Testing Strategies and Regulatory 
Efforts 
An Expert Panel Workshop was convened on 15-19 May 2006 in Granada to discuss the 
options for incorporating knowledge on low-dose and mixture effects in testing strategies 
and regulatory efforts. Invited attendees represented national regulatory agencies, NGOs 
and research organisations. A representative from Schering AG, Berlin, Germany was 
contacted and invited, but his company was uninterested and did not grant permission to 
attend. The workshop itself was very productive. The panelists worked on a stepped 
procedure for mixtures regulation and risk assessment.  
 
First considerations were to which chemicals should be included for EDC mixture 
regulation, and a decision on this issue depends on an answer to the question as to how to 
define what an EDC should be. It was felt that it is important to distinguish “mode of 
action” from “effects”. “Endocrine disruption” is a mode of action relevant to 
developmental and reproductive toxicity, but not an effect. Instead, this mode of action 
can give rise to a plethora of different effects. Mechanistic considerations open the way 
for grouping EDCs according to test results in “mode of action” screens, as with the 
customary classification into “estrogens”, “(anti)androgens”, “thyroid-actives” (EAT). 
However, the panelists recognised that this classification, with its emphasis on steroid and 
thyroid receptor interactions, does not capture all known endocrine effects and therefore 
suggested to include as additional category “others”, thus: EATO. The “mode of action” 
screen classification leads into a dilemma: The EATO grouping is of limited relevance for 
risk assessment, because the predictive value of such screening outcomes for the 
occurrence of (adverse) effects is questionable. For example, not all androgen receptor 
antagonists produce responses typical of disruption of male sexual development (such as 
NR, altered AGD etc). For estrogens, in vivo effect models capturing the conditions of 
concern in the human (e.g. breast cancer) are not available. Furthermore, screens are 
imperfect, as exemplified by the case of certain phthalate esters which disrupt male sexual 
development by interfering with steroid synthesis, and not by receptor interactions, yet 
many antiandrogen screening tools do not detect these phthalates. On the other hand, a 
grouping of EDCs in a phenomenological fashion according to effects is not currently 
possible, because too few chemicals have been tested in relevant toxicity studies, or 
because the appropriate tests are not yet available. This situation is not likely to change in 
the foreseeable future.  
 
An all-encompassing solution is not on the horizon, however, for specific chemicals, 
effects and exposure scenarios it is now well established that EDCs can act in an additive 
fashion. Therefore, there are possibilities for utilising existing knowledge and data for 
making progress with risk assessment and regulation that takes account of mixture 
effects. Several examples and exposure settings were discussed including: a) vitellogenin 
induction in fish from cumulative exposure to estrogenic chemicals (so-called mixture 
maps); b) NR and changes in AGD in the rat; c) Spiggin induction in the stickleback and 
d) internal exposure to estrogens in women. Conclusions were that CA is a powerful risk 
assessment tool for cumulative exposure in these examples. The panelists highlighted that 
knowledge about realistic exposure scenarios for EDC mixtures is fragmentary. In most 
cases, we simply do not know enough about the identity of EDC that co-occur in food, 
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environmental matrices or human tissues, let alone their levels. This presents a formidable 
bottleneck to rational risk assessment for combined exposures – some participants even 
thought that this lack of data is the obstacle to making progress. Thus, there is a need to 
deal with knowledge gaps by making informed assumptions, and a step-wise approach, 
depending on the quality of data available, was discussed. 
 
The following situations could be distinguished: a) In some cases, sufficient knowledge 
about the identity and levels of relevant EDCs is available – in these situations dose 
addition can be applied; b) More often, however, there is uncertainty as to whether 
specific EDCs are able to induce the effects under consideration, but there may be some 
reason for concern. In these cases, a “mixture assessment factor” could be applied for 
such EDC, so as to enable risk assessors to proceed and c) If no data or information is 
available, it was considered to apply a default mixture assessment factor, making certain 
assumptions about the likely number of chemicals in the mixture. 
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POLICY RELATED BENEFITS 
 
The results of EDEN are of considerable importance in providing better chemicals risk 
assessment and regulation in the European Union. The following project findings have 
policy relevant benefits: 
 
• The observation that no individual EDC at relevant exposure levels could be 
shown to be associated with endocrine-related disorders in the human highlights 
the importance of developing better biomarkers that capture cumulative exposure 
to EDC. Very likely, this should involve biological measures of cumulative 
internal exposure. This finding also presents a major challenge to risk assessment 
and risk reduction measures: If the contribution of single chemicals to possible 
risks stemming from endocrine disruption is small, then regulatory approaches 
have to be developed that adopt a holistic approach and capture the entirety of 
endocrine active chemicals, across various regulatory arenas, including pesticides, 
non-pesticide contaminants, and chemicals used in consumer products and 
personal care products. 
 
• The realisation that the testing and screening for EDC effects has not kept up with 
advances in our understanding of rapid signalling events triggered in the wake of 
steroid receptor activations should stimulate the development and validation of 
additional screening tools that are able to capture these signalling events. This is 
to avoid that endocrine active agents are overlooked. 
 
• Of particular concern are the observed declines in male reproductive health in 
parts of Europe, especially in Germany and in relation to the narrowing of the 
differences between Finland and Denmark. These findings are policy relevant in 
as far as they highlight the need to take urgent action to avoid personal suffering 
and an elevation of public health costs. 
 
• The EDEN project has provided evidence that the application of hypothesis 
testing methods which aims at estimating no-observed-adverse-effect-levels 
(NOAEL) is inadequate for capturing low-dose effects of EDC. Regression-based 
approaches with their benchmark dose limits should replace NOAEL as the basis 
for establishing acceptable human exposure levels. Ideally, mandatory risk 
assessment procedures in the EU should be amended to combine hypothesis 
testing and regression methods in a framework that utilises the strengths of both 
methodologies by making considerations of statistical detection limits and 
statistical power the starting point of testing procedures. Implementation of this 
framework will require a significant change in toxicological testing practice and 
regulatory policy in Europe, but will have considerable benefits in providing 
better protection for European citizens. 
 
• The extensive experimental mixture studies carried out in the EDEN project have 
significantly advanced knowledge about determinants and factors that govern the 
joint action of similarly acting EDC. Pragmatic risk assessment approaches that 
take mixture effects into consideration are now a viable proposition. 
Implementation of such approaches in relevant procedures should be pursued with 
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vigour, because the customary chemical-by-chemical approach to risk assessment 
will likely lead to underestimations of risk when exposure is to a large number of 
similarly acting EDC. 
 
  
 
 
 
